WO2004087724A1 - PROCESS FOR PRODUCING α,ß,Ϝ-SUBSTITUTED CYCLOPENTANONE DERIVATIVE - Google Patents

PROCESS FOR PRODUCING α,ß,Ϝ-SUBSTITUTED CYCLOPENTANONE DERIVATIVE Download PDF

Info

Publication number
WO2004087724A1
WO2004087724A1 PCT/JP2004/004484 JP2004004484W WO2004087724A1 WO 2004087724 A1 WO2004087724 A1 WO 2004087724A1 JP 2004004484 W JP2004004484 W JP 2004004484W WO 2004087724 A1 WO2004087724 A1 WO 2004087724A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
formula
unsubstituted
carbon atoms
Prior art date
Application number
PCT/JP2004/004484
Other languages
French (fr)
Japanese (ja)
Inventor
Akira Onodera
Yohei Kobashi
Yoshihiro Kimura
Koumei Ohta
Chihiro Yokoo
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to JP2005504234A priority Critical patent/JP4591778B2/en
Publication of WO2004087724A1 publication Critical patent/WO2004087724A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • C07F7/1872Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888

Definitions

  • the present invention relates to a, ⁇ , ⁇ -substitution useful as a pharmaceutical or a synthetic intermediate thereof.
  • ⁇ , ⁇ -Substituted cyclopentenonone derivatives are useful as pharmaceuticals or their intermediates.
  • 13,14-didehydroprostaglandin derivatives (compounds represented by the following formula), which are ⁇ ,, ⁇ -substituted cyclopentenonone derivatives having a triple bond at the 13-position, have recently attracted attention as compounds having a strong platelet aggregation inhibitory action (Japanese Patent Application Laid-Open No. Hei 6-192922).
  • the first example is a method for producing a 13,14-didehydroprostaglandin E derivative using the key reaction of ring opening of an epoxide with an organoaluminum acetylide reagent as shown in Reaction Formula 1 below (J. Fr. i ed et al., Te trahedron Letters, 1973, 14, 3899-3902.).
  • the second example is a production example using Corey lactone as a starting material, as shown in the following reaction formula 2.
  • the dehydrohalogenation reaction is allowed to proceed during the Wittig reaction to form a triple bond at the 13-position, resulting in 13,14-didehydroprostaglandin E.
  • This is a method for producing derivatives ( Gandolfi et al., ⁇ Farmaco Edition Sciences, 27, 1255 (1972).)
  • a third example is a method for producing a 13,14-didehydroprostaglandin ⁇ derivative by reacting an ⁇ , ⁇ -substituted cyclopentenone derivative with an organometallic reagent represented by the following formula [ ⁇ ] (Patent No. 2) No. 5,366,226), and the claims contain an organometallic reagent containing a triple bond [ ⁇ ], but there is no description of the examples.
  • an organoaluminum acetylide reagent is allowed to act on a cyclopentenone derivative having a getylaminomethyl group at the ⁇ -position to form an exomethylene compound, and then the ⁇ side chain is formed.
  • This is a method for producing a 13,14-didehydroprostaglandin derivative by adding Michael (F. Sato et al., J. Org. Chem., 1991, 56, 3205-3207.).
  • OTBS (T S) R1 alkyl group, cyclohexyl group
  • the a side chain is introduced stepwise, which is advantageous for producing a wide variety of derivatives.
  • it can be obtained by the introduction reaction of i3 side chain.
  • the ratio of the trans-form to the cis-form of the exo-methylene form fluctuates greatly, from 1.5 to 23: 1, making it difficult to obtain the desired trans-form stably (see Table 1).
  • the present inventors have made intensive studies to achieve the above object, and as a result, in the presence of a trialkylsilyl triflate, an a, r-substituted cyclopentenone derivative represented by the formula [I] was converted to a compound represented by the formula [III].
  • a substituted ethynyl organometallic reagent shown By reacting the substituted ethynyl organometallic reagent shown, a substituted ethynyl group can be introduced at the / 3 position in a highly stereoselective manner.
  • the present inventors have found a process for obtaining a 1,3-i-substituted cyclopentene nonone derivative with higher yield and higher stereoselectivity than ever before, and completed the present invention.
  • X 1 and X 2 are the same or different and represent an oxygen atom, a sulfur atom, a methylene group, a vinylene group, an ethynylene group or an arelenylene group, and n and q are the same or different and represent an integer of 0 to 6, ni and p are the same or different and each represent an integer of 0 to 2, r represents an integer of 0 to 3.
  • R 1 represents a hydrogen atom, a nitrile group
  • -OR 6 (formula Wherein R 6 represents a hydroxyl-protecting group.)
  • -C00R 7 wherein, R 7 is a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, a substituted or unsubstituted carbon atom number) 2 to 10 alkenyl groups, substituted or unsubstituted alkynyl groups, 2 to 10 alkynyl groups, substituted or unsubstituted cycl
  • R 8 is. Represents an alkyl group of one to six carbon atoms
  • BrZn or LiR 8 3 Al indicates, R 3 is a substituted or unsubstituted carbon atoms 1 to 1 0 alkyl groups, substituted or unsubstituted alkenyl groups having 2 to 10 carbon atoms, substituted or unsubstituted alkynyl groups having 2 to 10 carbon atoms, substituted or unsubstituted carbon atoms
  • Z represents a hydrogen atom or Z′R 4 (wherein Z ′ represents an oxygen atom or a sulfur atom, and R 4 represents a hydroxyl-protecting group
  • R5 represents a trialkylsilyl group
  • A, RR 2, R 3 and Z are Ru as defined der above.
  • the method for producing an ⁇ , ⁇ , ⁇ -substituted cyclopentene non-trialkylsilyl enol ester represented by the formula:
  • a non-aqueous condition of an ⁇ , ⁇ , ⁇ -substituted cyclopentene non-trialkylsilyl enol ether represented by the formula [V]
  • the substituted or unsubstituted alkyl group having 1 to 10 carbon atoms means a linear or branched alkyl group, such as a methyl group, an ethyl group, an ⁇ -propyl group, and an isopropyl group.
  • ⁇ -butyl group isobutyl group, t_butyl group, n-pentyl group, n-hexyl group, 2-methylpentyl group, cyclopentylmethyl group, cyclohexylmethyl group, cycle Hexoxyloxymethyl, benzyl, phenoxymethyl, 2-methoxyethyl, 2-chloroisopropyl, 2-methylhexyl, 2,5-dimethylhexyl, 2,6-dimethylheptyl Group, 2- (2, -methylcyclohexyl) pentyl group, n-octyl group, 3- (3'-methoxyphenyl) octyl group, 5-chloromethoxyheptyl group, n-decanyl group .
  • the substituent in the alkyl group is not particularly limited as long as it does not participate in the reaction.
  • examples include a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkyloxy group having 3 to 10 carbon atoms, and phenyl.
  • Alkyl, cycloalkyloxy, phenyl and phenoxy groups are unsubstituted, one or more halogen atoms, linear or branched alkyl groups having 1 to 4 carbon atoms or carbon atoms It may have several to four substituents such as a linear or branched alkoxy group.
  • halogen atom examples include fluorine, chlorine, bromine, and iodine.
  • linear or branched alkyl group having 1 to 4 carbon atoms examples include a methyl group, an ethyl group, an isopropyl group and a t-butyl group.
  • Examples of the linear or branched alkoxy group having 1 to 4 carbon atoms include a methoxy group, an ethoxy group, an isopropyloxy group, an 11-butoxy group and a t-butoxy group.
  • the substituted or unsubstituted alkenyl group having 2 to 10 carbon atoms means a linear or branched alkenyl group, such as a bier group, an aryl group, a 2,6-dimethyl-5-heptenyl group, 1,3-butadienyl group, ⁇ -propenyl-butenyl group, 4-pentenyl group, 3-chloro-1,5-hexagenenyl group, 2-methyl-4-pentenyl group,-(1'-ethoxyl) 2-methyl-4-pentenyl group, 3-ethyl-4- (4'-methoxycyclohexyl) -1,5-hexenyl group and 3-isopropyl-4-pentenyl group.
  • a bier group such as a bier group, an aryl group, a 2,6-dimethyl-5-heptenyl group, 1,3-butadienyl group, ⁇ -propenyl-butenyl
  • the substituent in the alkenyl group is not particularly limited as long as it does not participate in the reaction.
  • examples include a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkyloxy group having 3 to 10 carbon atoms, and phenyl.
  • cycloalkyl group, cycloalkyloxy group, phenyl group and phenoxy group are unsubstituted, one or more halogen atoms, linear or branched having 1 to 4 carbon atoms. It may have a substituent such as a chain alkyl group or a linear or branched alkoxy group having 1 to 4 carbon atoms.
  • the substituted or unsubstituted alkynyl group having 2 to 10 carbon atoms means a linear or branched alkynyl group, for example, 2-propynyl group, n-butynyl group, n-decynyl group, 2- Bromo-3-pentynyl, 2-methyl-5-heptynyl, 2-methoxy-6-methyl-7-en-3-octynyl, 3-cyclohexyloxy-1-en-4- A xynyl group.
  • the substituent in the alkynyl group is not particularly limited as long as it does not participate in the reaction, for example, a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkyloxy group having 3 to 10 carbon atoms, phenyl Group, phenoxy group, linear or branched alkoxy group having 1 to 4 carbon atoms, halogen atom and linear or branched alkenyl group having 2 to 6 carbon atoms.
  • One or more selected groups may be mentioned. Among them, a cycloalkyl group, a cycloalkyloxy group, a phenyl group and a phenoxy group are unsubstituted.
  • One or more halogen atoms, 1 carbon atom It may have a substituent such as a linear or branched alkyl group having 1 to 4 carbon atoms or a linear or branched alkoxy group having 1 to 4 carbon atoms.
  • a linear or branched alkenyl group having 2 to 6 carbon atoms is, for example, a vinyl group, a propenyl group, a 2-methyl-2-butenyl group, a 1,3-butadienyl group, a 2,4- Dimethyl-1,4-pentenyl phenyl group.
  • a linear or branched alkyl group having 1 to 6 carbon atoms is, for example, a methyl group, an ethyl group, an isopropyl group, an n-propyl group, an n-butyl group, a t-butyl group, a hexyl group Are listed.
  • a substituted or unsubstituted cycloalkyl group having 3 to 10 carbon atoms is, for example, a cycl group, a cyclobutyl group, a cyclopentyl group, a 2,4-dimethylcyclopentyl group, a cyclohexyl group, a 2-methylcyclo group.
  • the substituent in the cycloalkyl group is not particularly limited as long as it does not participate in the reaction.
  • Examples of the substituted or unsubstituted phenyl group include a phenyl group, a 4-bromophenyl group, and a 2-methyl-4-methoxyphenyl group.
  • the substituent in the phenyl group is not particularly limited as long as it does not participate in the reaction.
  • examples include a halogen atom, a linear or branched alkyl group having 1 to 4 carbon atoms, and a carbon atom having 1 to 4 carbon atoms.
  • Examples of the substituted or unsubstituted phenoxy group include a phenoxy group, a 2-methylphenoxy group, a 2-chlorophenoxy group, and a 4-isopropoxyphenoxy group.
  • the substituent in the phenoxy group is not particularly limited as long as it does not participate in the reaction.
  • examples include a halogen atom, a linear or branched alkyl group having 1 to 4 carbon atoms, and a carbon atom having 1 to 4 carbon atoms.
  • Examples of the substituted or unsubstituted cycloalkyloxy group having 3 to 10 carbon atoms include a 2-methylcyclohexyloxy group and a 3-bromooxyheptyloxy group.
  • the substituent in the cycloalkyloxy group is not particularly limited as long as it does not take part in the reaction.
  • examples thereof include an octogen atom, a linear or branched alkyl group having 1 to 4 carbon atoms, and a carbon atom.
  • One or a plurality of groups selected from the group of linear or branched alkoxy groups having a number of 1 to 4 are exemplified.
  • the protecting group for the lipoxyl group may be any group that functions as a protecting group in each reaction, for example, a linear or branched alkyl group having 1 to 6 carbon atoms, a benzyl group, a substituted benzyl group. And diphenylmethyl group, methoxymethyl group, trichloroethyl group, triethylsilyl group, t-butyldimethylsilyl group, 2- (trimethylylsilyl) ethyl group, and aryl group.
  • the substituted benzyl group is not particularly limited as long as it does not participate in the reaction.
  • the hydroxyl-protecting group may be any group that functions as a protecting group in each reaction, and includes a trialkylsilyl group, an alkoxyalkyl group, an aralkyloxyalkyl group, a trityl group or a tetrahydropyranyl (THP) group.
  • THP tetrahydropyranyl
  • trimethylsilyl group triethylsilyl group, t-butyldimethylsilyl group, methoxymethyl group, benzyloxymethyl group, acetyl group, benzoyl group, benzyl group, P-methoxybenzyl group, p-methoxybenzyl group, And a tri (P-methoxyphenyl) methyl group and a benzyloxycarbonyl group.
  • the protecting group for the thiol group may be any group that functions as a protecting group in each reaction, and examples thereof include a benzyl group, a 4-methoxybenzyl group, a diphenylmethyl group, a trityl group, a methoxymethyl group, and a benzyloxycarbonyl group. .
  • the trialkylsilyl triflate includes, for example, t-butyldimethylsilyl triflate.
  • the trialkylsilyl group includes, for example, a trimethylsilyl group, a t-butyldimethylsilyl group, and a triethylsilyl group.
  • the acid includes a mineral acid, an organic acid, a Lewis acid, and the like. More specifically, the mineral acid includes, for example, an organic solvent solution of hydrogen chloride, concentrated sulfuric acid, and phosphoric acid.
  • organic acid examples include trifluoroacetic acid, benzenesulfonic acid, P-toluenesulfonic acid, methanesulfonic acid, and dodecylbenzene sulfonic acid.
  • Lewis acids include, for example, titanium (IV) chloride, zinc chloride, zinc bromide, zinc trifluoromethanesulfonate, magnesium perchlorate, magnesium trifluoromethanesulfonate, boron trifluoride-ethyl chloride complex, aluminum chloride ( 111) and getyl aluminum chloride.
  • the compound of the formula [I] can be produced, for example, according to the method described in Patent No. 2570796, Eur. J. Org. Chem. 1999, 265-2662, and the like.
  • the compound of the formula [III] can be prepared according to a usual method for preparing an organometallic reagent.
  • organozinc reagent of the formula [III] M is BrZn
  • first heat active zinc and 1,2-dibromoethane in tetrahydrofuran to prepare a tetrahydrofuran solution of zinc bromide (ZnBr 2 ).
  • ZnBr 2 zinc bromide
  • it can be prepared by adding it to a separately prepared lithium salt represented by the formula [III] '»ii (CHI).
  • the amount of zinc bromide used is 0.5 to 2 equivalents, preferably 0.8 to 1.2 equivalents are good.
  • Organoaluminum ate complex can be prepared by adding trialkylaluminum (A1R 8 3) the lithium salt of the formula was prepared in the same manner as described above [III] '.
  • the amount of the trialkylaluminum used is 0.5 to 2 equivalents, preferably 0.8 to 1.2 equivalents, relative to the lithium salt.
  • the solvent used for the preparation of the compound of the formula [II] is not particularly limited and may be any solvent which does not inhibit the reaction, and examples thereof include tetrahydrofuran, geethylether, cyclopentyl methyl ether, toluene and hexane.
  • the compound of the formula [IV] can be produced, for example, by the following method.
  • the trialkylsilyl triflate is added to the compound of the formula [I] in an amount of 0.5 to 5 equivalents, preferably 0.8 to 5 equivalents.
  • the organic zinc reagent of the formula [III] is used in an amount of 0.5 to 5 equivalents, preferably 0.8 to 3 equivalents to the compound of the formula [I].
  • the reaction temperature is -100 to 50 ° C, preferably -80 to 30 ° C, and the reaction time is usually 5 minutes to 50 hours.
  • the formula [I] 0.5 to the Toriarukirushi Lil triflate 3 equivalents, preferably 0.8 to 2 equivalents, when the organoaluminate complex of the formula [III] is used in an amount of 0.5 to 4 equivalents, preferably 0.8 to 2 equivalents to the compound of the formula [I] Is good.
  • the reaction temperature is -100 to 20 ° C, preferably _80 to 0 ° C, and the reaction time is usually 5 minutes to 5 hours.
  • the solvent used in these reactions is not particularly limited as long as it does not inhibit the reaction, and examples thereof include tetrahydrofuran, getyl ether, cyclopentylmethyl ether, hexane, and toluene.
  • the compound of the formula [V] can be produced, for example, by the following method, that is, a method of reacting a compound of the formula [IV] with an acid under non-aqueous conditions.
  • the acid include a mineral acid, an organic acid, and a Lewis acid, and preferably include benzenesulfonic acid, P-toluenesulfonic acid, methanesulfonic acid, and magnesium perchlorate.
  • the acid is used in an amount of 0.5 to 3 equivalents, preferably 1 to 2 equivalents, to the compound of the formula [IV].
  • the reaction temperature is ⁇ 100 to 50 ° C., preferably ⁇ 80 to 30 ° C., and the reaction time is usually 0.5 to 20 hours.
  • the solvent used in this reaction is not particularly limited as long as it does not inhibit the reaction, and examples include tetrahydrofuran, getyl ether, dichloromethane, chloroform, toluene, and acetonitrile.
  • the side chain is highly stereoselectively induced in the trans configuration with respect to the ⁇ side chain.
  • a compound of the formula [IV] is reacted with a compound of the formula [I] and an organometallic reagent of the formula [111] in the presence of one or more equivalents of a trialkylsilyl triflate. This is a process for obtaining a compound of the formula [V] at a stroke without isolating the compound of formula (I).
  • the amount of the organozinc reagent of the formula [III] (M is BrZn) to the compound of the formula [I] is 0.8 to 2 equivalents, preferably 1 to 1.5 equivalents, and the amount of topyldimethylsilyl triflate used is 1 to 3 equivalents, preferably 1., based on the organozinc reagent of the formula [III] (M is BrZn). 5-2.5 It is better to use the equivalent.
  • the reaction temperature is ⁇ 100 to 50 ° C., preferably ⁇ 80 to 30 ° C., and the reaction time is usually 150 hours.
  • the solvent used in this reaction is not particularly limited as long as it does not inhibit the reaction, and examples thereof include tetrahydrofuran, getyl ether, cyclopentyl methyl ether, hexane, and toluene.
  • THF represents tetrahydrofuran
  • Me represents a methyl group
  • TBS represents a t-butyldimethylsilyl group
  • TES represents a triethylsilyl group
  • HPLC high-performance liquid chromatography
  • Dissolve compound 9 (0.20 g, 0.34 tmol) showing relative configuration in dichloromethane (4. OiiiL), add benzenesulfonic acid (0.06 g, 0.38 mmol) at -78 ° C, and at the same temperature for 3 hours Stirred. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
  • the substituted echel side chain at the i3 position is introduced into the trans configuration in a highly stereoselective manner with respect to the protected hydroxyl group at the a position to efficiently obtain a trans form having a desired high physiological activity.
  • Table 3 The right column of Table 3 shows the results of the present invention, and the left column shows the results of the conventional method (Table 1).
  • the detrialkylsilylation reaction with an acid under non-aqueous conditions of the present invention can control the ⁇ side chain to the trans configuration in a highly stereoselective manner with respect to the 3 side chains.
  • Table 4 shows the results of the detrialkylsilyl cosmic reaction of the t-butyldimethylsilyl enol ether.
  • the results for the hydrous system are shown in Reaction Formula 4.
  • the ratio of the trans-form to the cis-form in the detrialkylsilylation reaction by an acid under non-aqueous conditions of the present invention is from 24 to 220: 1, and the desired trans-form is higher than that in a water-containing system. Highly stereoselective. Table 4
  • Compound 1 and compound 8 used in the present invention can be obtained by the following methods (Reference Examples 1 to 13), but are not limited to these Reference Examples.
  • the production method of the present invention provides a safer and more stereoselective method for various substituted ethyl groups at the ⁇ -position of an ⁇ , ⁇ -substituted cyclobennone derivative having a desired side chain than the conventional method. It is possible to provide a synthesis of Q !, a 3, ⁇ -substituted cyclopentenonone derivative, which is very useful as an industrially suitable drug or an intermediate thereof.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

A practical process by which an α,ß,Ϝ-substituted cyclopentanone derivative which is useful as a medicine or an intermediate for medicine production is more efficiently and safely produced than known techniques. The compound having a desired stereostructure can be highly stereoselectively produced in a satisfactory yield.

Description

明細  Statement
a , i3,ァ-置換シクロペン夕ノン誘導体の製造法 Method for producing a, i3, α-substituted cyclopenenones
技術分野 Technical field
本発明は、 医薬品あるいはその合成中間体として有用な a, ^,ァ -置換  The present invention relates to a, ^, α-substitution useful as a pharmaceutical or a synthetic intermediate thereof.
'誘導体の製造法に関する。  'Regarding the method for producing derivatives.
背景技術Background art
, β ,ァ-置換シクロペン夕ノン誘導体は、 医薬品あるいはその中間体として有用な 物質である。  , β, α-Substituted cyclopentenonone derivatives are useful as pharmaceuticals or their intermediates.
特に 13位に 3重結合を有する α, ,ァ-置換シクロペン夕ノン誘導体である 13, 14 -ジ デヒドロプロスタグランジン 誘導体 (下記式に示す化合物) は強い血小板凝集抑制 作用を有する化合物として近年注目されている (特開平 6— 1 9 2 2 1 9号公報) 。  In particular, 13,14-didehydroprostaglandin derivatives (compounds represented by the following formula), which are α ,, α-substituted cyclopentenonone derivatives having a triple bond at the 13-position, have recently attracted attention as compounds having a strong platelet aggregation inhibitory action (Japanese Patent Application Laid-Open No. Hei 6-192922).
Figure imgf000002_0001
Figure imgf000002_0001
X: 0 or S  X: 0 or S
R: H or He しかしながら、 これまでに 13, 14-ジデヒドロプロスタグランジン E誘導体を製造する 方法は、 極めて数が少なく、 我々の知る限り 4例しか知られてない。 1例目は、 下記反 応式 1に示すように有機アルミニウムァセチリド試薬によるエポキシドの開環を鍵反応 とする 13, 14-ジデヒドロプロスタグランジン E誘導体の製造法である (J. Fr i edら, Te trahedron Let ters, 1973, 14, 3899-3902. ) 。 R: H or He However, there are very few methods for producing 13,14-didehydroprostaglandin E derivatives so far, and to our knowledge only four examples are known. The first example is a method for producing a 13,14-didehydroprostaglandin E derivative using the key reaction of ring opening of an epoxide with an organoaluminum acetylide reagent as shown in Reaction Formula 1 below (J. Fr. i ed et al., Te trahedron Letters, 1973, 14, 3899-3902.).
Figure imgf000003_0001
Figure imgf000003_0001
この製造法では、 製造中間体である光学活性エポキシドの製造が繁雑であり、 光学分割 効率も悪く、 また鍵反応であるエポキシドの開環反応における位置選択性も低く、 実用 性に欠ける。 In this production method, the production of an optically active epoxide, which is a production intermediate, is complicated, the optical resolution efficiency is poor, and the regioselectivity in the ring-opening reaction of the epoxide, which is a key reaction, is low, so that it lacks practicality.
2例目は、 下記反応式 2で示すように、 Coreyラクトンを出発原料して用いる製造例 である。 Wi t t ig反応時に脱ハロゲン化水素反応を同時に進行させて、 13位に三重結合を 構築し、 13, 14-ジデヒドロプロスタグランジン E。誘導体を製造する方法である ( Gandolfiら, Π Farmaco Edition Sciences, 27, 1255 (1972).) The second example is a production example using Corey lactone as a starting material, as shown in the following reaction formula 2. At the same time, the dehydrohalogenation reaction is allowed to proceed during the Wittig reaction to form a triple bond at the 13-position, resulting in 13,14-didehydroprostaglandin E. This is a method for producing derivatives ( Gandolfi et al., Π Farmaco Edition Sciences, 27, 1255 (1972).)
Figure imgf000004_0001
この製造法は、 工業的規模で入手可能な Coreyラクトンを用いていること、 また Wittig反応により α側鎖を導入する際に iS側鎖の脱ハロゲン化水素反応が進行し、 三重 結合が構築されるなど実用性がある。 しかしながら、 0:側鎖中の二重結合と jS側鎖中の 三重結合との選択的還元が求められることから、 13, 14- Ex誘導体の実用的製造法とは言い難い。 3例目は、 α,ァ-置換シクロペンテノン誘導体に下記式 [Β]で表される有機金属試薬 を作用させて 13, 14-ジデヒドロプロスタグランジン Ε誘導体を製造する方法 (特許第 2 5 3 6 0 2 6号公報) であり、 特許請求項には、 三重結合を含む有機金属試薬 [Β]が 含まれているがその実施例の記載は無い。
Figure imgf000004_0001
This production method uses Corey lactone, which is available on an industrial scale, and the dehydrohalogenation reaction of the iS side chain progresses when the α side chain is introduced by the Wittig reaction, creating a triple bond. There is practicality such as. However, 0: since the selective reduction of the triple bond of a double bond and jS side chain in the side chain is found, 13, it is hard to say that practical preparation of 14- E x derivative. A third example is a method for producing a 13,14-didehydroprostaglandin Ε derivative by reacting an α, α-substituted cyclopentenone derivative with an organometallic reagent represented by the following formula [Β] (Patent No. 2) No. 5,366,226), and the claims contain an organometallic reagent containing a triple bond [Β], but there is no description of the examples.
CuCNLh [B] CuCNLh [B]
0Y  0Y
4例目は、 下記反応式 3に示すように、 α位にジェチルァミノメチル基を有するシク 口ペンテノン誘導体に有機アルミニウムァセチリド試薬を作用させてェキソメチレン体 とした後、 α側鎖をマイケル付加することにより 13 , 14-ジデヒドロプロスタグランジン Ε誘導体を製造する方法である (F. Satoら, J. Org. Chem. , 1991 , 56, 3205-3207. ) 反応式 3 In the fourth example, as shown in the following reaction formula 3, an organoaluminum acetylide reagent is allowed to act on a cyclopentenone derivative having a getylaminomethyl group at the α-position to form an exomethylene compound, and then the α side chain is formed. This is a method for producing a 13,14-didehydroprostaglandin derivative by adding Michael (F. Sato et al., J. Org. Chem., 1991, 56, 3205-3207.).
Figure imgf000005_0001
Figure imgf000005_0001
IZn (CN)Cu C02Me IZn (CN) Cu C0 2 Me
鎖)  Chain)
TMSC I  TMSC I
Figure imgf000005_0002
Figure imgf000005_0002
R1  R1
=  =
OTBS (T S) R1 =アルキル基、 シクロへキシル基  OTBS (T S) R1 = alkyl group, cyclohexyl group
この製造法では 3側鎖を導入後、 a側鎖を段階的に導入しており、 多種多様な誘導体を 製造するには有利である。 しかしながら、 この製造法では i3側鎖の導入反応で得られる ェキソメチレン体のトランス体とシス体の生成比が 1. 5〜23: 1と大きく変動し、 所望 するトランス体を安定して得ることが困難である (表 1参照) 。 In this production method, after introducing the three side chains, the a side chain is introduced stepwise, which is advantageous for producing a wide variety of derivatives. However, in this production method, it can be obtained by the introduction reaction of i3 side chain. The ratio of the trans-form to the cis-form of the exo-methylene form fluctuates greatly, from 1.5 to 23: 1, making it difficult to obtain the desired trans-form stably (see Table 1).
表 1  table 1
Figure imgf000006_0001
卜ランス
Figure imgf000006_0001
Trance
82 : 14  82: 14
0TBS  0TBS
83 : 8 83: 8
0TBS  0TBS
90 : 490: 4
Figure imgf000006_0002
Figure imgf000006_0002
0 ¾J , 3 J  0 ¾J, 3 J
50 : 19 また、 α'側鎖の有機銅試薬を調製する際に毒物であるシアン化銅を使用しており、 実用 化に当たっては安全対策、 環境対策が必要となるなど製造コスト面で不利である。 一方、 卜リアルキルシリルトリフラー卜存在下、 α -置換シクロアルケノン誘導体へ の有機金属試薬のマイケル付加反応の報告例はある (Kimら, Te t rahedron Le t ters, 1990, 31 , 7627-7630. , Kimら, Syn l et t, 1995, 163-164. ) 。 しかしながら、 これまで にひ, i3 -不飽和シクロペンテノン環のァ位に水酸基または保護された水酸基を有する誘 導体に本反応を応用した例はなく、 しかもァ位水酸基または保護された水酸基に対して50:19 In addition, toxic copper cyanide is used when preparing the α 'side chain organocopper reagent, which is disadvantageous in terms of manufacturing costs, such as the necessity of safety measures and environmental measures in practical use. is there. On the other hand, there is a report of a Michael addition reaction of an organometallic reagent to an α-substituted cycloalkenone derivative in the presence of a trialkylsilyl triflate (Kim et al., Tetrahedron Letters, 1990, 31, 7627-7630). , Kim et al., Synlett, 1995, 163-164.). However, there has been no application of this reaction to a derivative having a hydroxyl group or a protected hydroxyl group at the a-position of the i3-unsaturated cyclopentenone ring. hand
、 i3側鎖をトランス配置に高立体選択的に導入する方法は知られていない。 However, a method of introducing the i3 side chain into the trans configuration with high stereoselectivity is not known.
また、 得られた α , β ,ァ-置換シクロペン夕ノントリアルキルシリルエノールエーテ ル体に非水条件下、 鉱酸、 有機酸あるいはルイス酸を作用させて脱トリアルキルシリル 化することにより、 α側鎖を i3側鎖に対して高立体選択的にトランス配置に誘導する例 は知られていない。 発明の'開示 Further, by subjecting the obtained α, β, α-substituted cyclopentene non-trialkylsilyl enol ether to a non-aqueous condition with a mineral acid, an organic acid or a Lewis acid to remove the trialkylsilyl, There is no known example of directing the side chain to the trans configuration in a highly stereoselective manner with respect to the i3 side chain. 'Disclosure of the invention'
本発明者らは、 上記目的を達成するため鋭意検討を行った結果、 トリアルキルシリル トリフラートの存在下、 式 [I]で表される a, r -置換シクロペンテノン誘導体に式 [I I I ]で表される置換ェチニル有機金属試薬を反応させることにより、 /3位に高立体選択的 に置換ェチニル基を導入することができ、 さらに α側鎖の立体配置を制御しながら式 [V ]で表される , i3,ァ-置換シクロペン夕ノン誘導体を、 従来より良好な収率かつ高立体 選択的に得る製造法を見出し、 本発明を完成した。  The present inventors have made intensive studies to achieve the above object, and as a result, in the presence of a trialkylsilyl triflate, an a, r-substituted cyclopentenone derivative represented by the formula [I] was converted to a compound represented by the formula [III]. By reacting the substituted ethynyl organometallic reagent shown, a substituted ethynyl group can be introduced at the / 3 position in a highly stereoselective manner. Thus, the present inventors have found a process for obtaining a 1,3-i-substituted cyclopentene nonone derivative with higher yield and higher stereoselectivity than ever before, and completed the present invention.
すなわち、 本発明は、 以下の様に示される。 That is, the present invention is shown as follows.
1 ) 下記式 [I] 1) The following formula [I]
2
Figure imgf000007_0001
Two
Figure imgf000007_0001
[式中、 Aは式 [I I]
Figure imgf000007_0002
[Where A is the formula [II]
Figure imgf000007_0002
(式中、 X1及び X2は同一または異なって酸素原子、 硫黄原子、 メチレン基、 ビニレン基 、 ェチニレン基またはァレニレン基を示し、 n及び qは同一または異なって 0〜 6の整数 を示し、 ni及び pは同一または異なって 0〜 2の整数を示し、 rは 0〜 3の整数を示す。 ) で表される基を示し、 R1は水素原子、 二トリル基、 -OR6 (式中、 R6は水酸基の保護基 を示す。 ) または -C00R7 (式中、 R7は置換もしくは無置換の炭素原子数 1〜 1 0個のァ ルキル基、 置換もしくは無置換の炭素原子数 2〜 1 0個のアルケニル基、 置換もしくは 無置換の炭素原子数 2〜 1 0個のアルキニル基、 置換もしくは無置換の炭素原子数 3〜 1 0個のシクロアルキル基、 置換もしくは無置換のフエニル基またはカルボキシル基の 保護基を示す。 ) を示し、 R2は水酸基の保護基を示す。 ] で表されるひ,ァ -置換シクロ 誘導体と、 下記式 [I I I]
Figure imgf000008_0001
(In the formula, X 1 and X 2 are the same or different and represent an oxygen atom, a sulfur atom, a methylene group, a vinylene group, an ethynylene group or an arelenylene group, and n and q are the same or different and represent an integer of 0 to 6, ni and p are the same or different and each represent an integer of 0 to 2, r represents an integer of 0 to 3.), R 1 represents a hydrogen atom, a nitrile group, -OR 6 (formula Wherein R 6 represents a hydroxyl-protecting group.) Or -C00R 7 (wherein, R 7 is a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, a substituted or unsubstituted carbon atom number) 2 to 10 alkenyl groups, substituted or unsubstituted alkynyl groups, 2 to 10 alkynyl groups, substituted or unsubstituted cycloalkyl groups, having 3 to 10 carbon atoms, substituted or unsubstituted phenyl a group or a protecting group of carboxyl group.) indicates, R 2 is protected hydroxyl groups Represents a group. And an α-substituted cyclo derivative represented by the following formula [III]:
Figure imgf000008_0001
[式中、 Mは BrZnまたは LiR8 3Al (式中、 R8は炭素原子数 1〜 6個のアルキル基を示す。 ) を示し、 R3は置換もしくは無置換の炭素原子数 1〜1 0個のアルキル基、 置換もしく は無置換の炭素原子数 2〜1 0個のアルケニル基、 置換もしくは無置換の炭素原子数 2 〜1 0個のアルキニル基、 置換もしくは無置換の炭素原子数 3〜1 0個のシクロアルキ ル基、 置換もしくは無置換の炭素原子数 3〜1 0個のシクロアルキルォキシ基、 置換も しくは無置換のフエニル基または置換もしくは無置換のフエノキシ基を示し、 Zは水素 原子または Z'R4 (式中、 Z'は酸素原子または硫黄原子を示し、 R4は水酸基の保護基または チオール基の保護基を示す。 ) を示す。 ]で表される有機金属試薬とをトリアルキルシ リルトリフラートの存在下で反応させることを特徴とする下記式 [IV] [In the formula, M (wherein, R 8 is. Represents an alkyl group of one to six carbon atoms) BrZn or LiR 8 3 Al indicates, R 3 is a substituted or unsubstituted carbon atoms 1 to 1 0 alkyl groups, substituted or unsubstituted alkenyl groups having 2 to 10 carbon atoms, substituted or unsubstituted alkynyl groups having 2 to 10 carbon atoms, substituted or unsubstituted carbon atoms A cycloalkyl group having 3 to 10 cycloalkyl groups, a substituted or unsubstituted cycloalkyloxy group having 3 to 10 carbon atoms, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted phenoxy group; Z represents a hydrogen atom or Z′R 4 (wherein Z ′ represents an oxygen atom or a sulfur atom, and R 4 represents a hydroxyl-protecting group or a thiol-protecting group). Characterized by reacting with an organometallic reagent represented by the following formula in the presence of a trialkylsilyl triflate:
Figure imgf000008_0002
Figure imgf000008_0002
[式中、 R5はトリアルキルシリル基を示し、 A、 R R2、 R3および Zは前記と同意義であ る。 ]で表される α, β , τ -置換シク口ペン夕ノントリアルキルシリルエノ一ルェ一テル 体の製造法。 Wherein, R5 represents a trialkylsilyl group, A, RR 2, R 3 and Z are Ru as defined der above. The method for producing an α, β, τ-substituted cyclopentene non-trialkylsilyl enol ester represented by the formula:
2 ) 1 ) 記載の式 [IV] 中、 A、 R1 , R2、 R3、 R5及び Zは前記と同意義である。 ]で表 される α, β , τ -置換シクロペン夕ノントリアルキルシリルエノールエーテル体に非水 条件下、 酸を作用させて脱トリアルキルシリル化することを特徴とする下記式 [V]
Figure imgf000009_0001
2) In the formula [IV] described in 1), A, R 1 , R 2 , R 3 , R 5 and Z are as defined above. A non-aqueous condition of an α, β, τ-substituted cyclopentene non-trialkylsilyl enol ether represented by the formula [V]
Figure imgf000009_0001
[式中、 R R2、 R3および Zは前記と同意義である。 ]で表される a, i3,ァ-置換シク 口ペン夕ノン誘導体の製造法。 [Wherein, RR 2 , R 3 and Z are as defined above. A method for producing a, i3, α-substituted cyclopentene non-derivatives represented by the formula:
3 ) 1 ) 記載の式 [I] [式中、 A、 R1及び R2は前記と同意義である。 ]で表される α, τ - 置換シクロペンテノン誘導体と式 [III] [式中、 R3、 M及び Zは前記と同意義である。 ]で 表される有機金属試薬とを反応させる際に、 トリアルキルシリルトリフラー卜を 1当量 以上用いることを特徴とする下記式 [V] 3) The formula [I] described in 1) [wherein, A, R 1 and R 2 are as defined above. Α, τ-substituted cyclopentenone derivative represented by the formula [III] wherein R 3 , M and Z are as defined above. Wherein at least one equivalent of trialkylsilyl triflate is used in the reaction with the organometallic reagent represented by the formula [V]
Figure imgf000009_0002
Figure imgf000009_0002
[式中 A、 R1 , R2、 R3および Zは前記と同意義である。 ]で表される α , 3 ,ァ-置換シクロ ペン夕ノン誘導体の製造法。 Wherein A, R 1 , R 2 , R 3 and Z are as defined above. A method for producing an α, 3, α-substituted cyclopentenonone derivative represented by the formula:
本発明を詳細に説明するが、 例示されたものに特に限定されない。  The present invention will be described in detail, but is not particularly limited to those exemplified.
本発明において、 置換もしくは無置換の炭素原子数 1〜1 0個のアルキル基とは、 直 鎖状もしくは分枝鎖状アルキル基を示し、 例えばメチル基、 ェチル基、 η-プロピル基、 イソプロピル基、 η-ブチル基、 イソブチル基、 t _ブチル基、 n-ペンチル基、 n-へキシ ル基、 2-メチルペンチル基、 シクロペンチルメチル基、 シクロへキシルメチル基、 シク 口へキシルォキシメチル基、 ベンジル基、 フエノキシメチル基、 2-メトキシェチル基、 2 -クロ口イソプロピル基、 2-メチルへキシル基、 2, 5 -ジメチルへキシル基、 2, 6-ジメチ ルへプチル基、 2- (2,-メチルシクロへキシル) ペンチル基、 n-ォクチル基、 3- (3'-メ トキシフエ二ル) ォクチル基、 5-クロロメトキシへプチル基、 n-デカニル基が挙げられ る。 In the present invention, the substituted or unsubstituted alkyl group having 1 to 10 carbon atoms means a linear or branched alkyl group, such as a methyl group, an ethyl group, an η-propyl group, and an isopropyl group. , Η-butyl group, isobutyl group, t_butyl group, n-pentyl group, n-hexyl group, 2-methylpentyl group, cyclopentylmethyl group, cyclohexylmethyl group, cycle Hexoxyloxymethyl, benzyl, phenoxymethyl, 2-methoxyethyl, 2-chloroisopropyl, 2-methylhexyl, 2,5-dimethylhexyl, 2,6-dimethylheptyl Group, 2- (2, -methylcyclohexyl) pentyl group, n-octyl group, 3- (3'-methoxyphenyl) octyl group, 5-chloromethoxyheptyl group, n-decanyl group .
アルキル基における置換基とは、 反応に関与しなければ特に限定はされないが、 例え ば炭素原子数 3〜1 0個のシクロアルキル基、 炭素原子数 3〜1 0個のシクロアルキル ォキシ基、 フエニル基、 フエノキシ基、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状 アルコキシ基及び八ロゲン原子の群から選ばれる一つもしくは複数の基が挙げられ、 さ らにこれらのうちのシクロアルキル基、 シクロアルキルォキシ基、 フエニル基及びフエ ノキシ基は無置換、 一つもしくは複数のハロゲン原子、 炭素原子数 1〜 4個の直鎖状も しくは分枝鎖状アルキル基または炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルコ キシ基などの置換基を有していてもよい。  The substituent in the alkyl group is not particularly limited as long as it does not participate in the reaction.Examples include a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkyloxy group having 3 to 10 carbon atoms, and phenyl. Group, phenoxy group, linear or branched alkoxy group having 1 to 4 carbon atoms, and one or more groups selected from the group consisting of octylogen atoms. Alkyl, cycloalkyloxy, phenyl and phenoxy groups are unsubstituted, one or more halogen atoms, linear or branched alkyl groups having 1 to 4 carbon atoms or carbon atoms It may have several to four substituents such as a linear or branched alkoxy group.
ハロゲン原子とは例えばフッ素、 塩素、 臭素、 ヨウ素が挙げられる。  Examples of the halogen atom include fluorine, chlorine, bromine, and iodine.
炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルキル基とは例えばメチル基、 ェチ ル基、 イソプロピル基、 t-ブチル基が挙げられる。  Examples of the linear or branched alkyl group having 1 to 4 carbon atoms include a methyl group, an ethyl group, an isopropyl group and a t-butyl group.
炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルコキシ基とは例えばメトキシ基、 エトキシ基、 イソプロピルォキシ基、 11 -ブトキシ基、 t -ブトキシ基が挙げられる。  Examples of the linear or branched alkoxy group having 1 to 4 carbon atoms include a methoxy group, an ethoxy group, an isopropyloxy group, an 11-butoxy group and a t-butoxy group.
置換もしくは無置換の炭素原子数 2〜 1 0個のアルケニル基とは、 直鎖状もしくは分枝 鎖状アルケニル基を示し、 例えばビエル基、 ァリル基、 2, 6 -ジメチル -5-ヘプテニル基 、 1 , 3-ブタジェニル基、 Γ -プロぺニル-ブテニル基、 4-ペンテニル基、 3-クロ口- 1 , 5 - へキサジェニル基、 2 -メチル -4-ペンテニル基、 - (1'-エトキシェチル) -2-メチル -4- ペンテニル基、 3-ェチル -4- (4'-メトキシシクロへキシル) -1 , 5-へキサジェニル基、 3 - ィソプロピル- 4-ペンテニル基が挙げられる。 The substituted or unsubstituted alkenyl group having 2 to 10 carbon atoms means a linear or branched alkenyl group, such as a bier group, an aryl group, a 2,6-dimethyl-5-heptenyl group, 1,3-butadienyl group, Γ-propenyl-butenyl group, 4-pentenyl group, 3-chloro-1,5-hexagenenyl group, 2-methyl-4-pentenyl group,-(1'-ethoxyl) 2-methyl-4-pentenyl group, 3-ethyl-4- (4'-methoxycyclohexyl) -1,5-hexenyl group and 3-isopropyl-4-pentenyl group.
アルケニル基における置換基とは、 反応に関与しなければ特に限定はされないが、 例え ば炭素原子数 3〜1 0個のシクロアルキル基、 炭素原子数 3〜1 0個のシクロアルキル ォキシ基、 フエニル基、 フエノキシ基、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状 アルコキシ基及びハロゲン原子の群から選ばれる一つもしくは複数の基が挙げられ、 さ らにこれらのうちのシクロアルキル基、 シクロアルキルォキシ基、 フエニル基及びフエ ノキシ基は無置換、 一つもしくは複数のハロゲン原子、 炭素原子数 1〜 4個の直鎖状も しくは分枝鎖状アルキル基または炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルコ キシ基などの置換基を有していてもよい。 The substituent in the alkenyl group is not particularly limited as long as it does not participate in the reaction.Examples include a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkyloxy group having 3 to 10 carbon atoms, and phenyl. Group, a phenoxy group, a linear or branched alkoxy group having 1 to 4 carbon atoms, and one or more groups selected from the group consisting of halogen atoms. Among them, cycloalkyl group, cycloalkyloxy group, phenyl group and phenoxy group are unsubstituted, one or more halogen atoms, linear or branched having 1 to 4 carbon atoms. It may have a substituent such as a chain alkyl group or a linear or branched alkoxy group having 1 to 4 carbon atoms.
置換もしくは無置換の炭素原子数 2〜1 0個のアルキニル基とは、 直鎖状もしくは分 枝鎖状アルキニル基を示し、 例えば 2-プロピニル基、 n -プチニル基、 n-デキニル基、 2- ブロモ -3-ペンチニル基、 2 -メチル -5-ヘプチニル基、 2-メトキシ- 6-メチル -7-ェン- 3 - ォクチ二ル基、 3-シクロへキシルォキシ- 1 -ェン -4-へキシニル基が挙げられる。  The substituted or unsubstituted alkynyl group having 2 to 10 carbon atoms means a linear or branched alkynyl group, for example, 2-propynyl group, n-butynyl group, n-decynyl group, 2- Bromo-3-pentynyl, 2-methyl-5-heptynyl, 2-methoxy-6-methyl-7-en-3-octynyl, 3-cyclohexyloxy-1-en-4- A xynyl group.
アルキニル基における置換基とは、 反応に関与しなければ特に限定はされないが、 例え ば炭素原子数 3〜 1 0個のシクロアルキル基、 炭素原子数 3〜 1 0個のシクロアルキル ォキシ基、 フエニル基、 フエノキシ基、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状 アルコキシ基、 八ロゲン原子及び炭素原子数 2〜 6個の直鎖状もしくは分枝鎖状アルケ ニル基の群から選ばれる一つもしくは複数の基が挙げられ、 さらにこれらのうちのシク 口アルキル基、 シクロアルキルォキシ基、. フエニル基及びフェノキシ基は無置換. 一つ もしくは複数のハロゲン原子、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルキル 基または炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルコキシ基などの置換基を有 していてもよい。 The substituent in the alkynyl group is not particularly limited as long as it does not participate in the reaction, for example, a cycloalkyl group having 3 to 10 carbon atoms, a cycloalkyloxy group having 3 to 10 carbon atoms, phenyl Group, phenoxy group, linear or branched alkoxy group having 1 to 4 carbon atoms, halogen atom and linear or branched alkenyl group having 2 to 6 carbon atoms. One or more selected groups may be mentioned. Among them, a cycloalkyl group, a cycloalkyloxy group, a phenyl group and a phenoxy group are unsubstituted. One or more halogen atoms, 1 carbon atom It may have a substituent such as a linear or branched alkyl group having 1 to 4 carbon atoms or a linear or branched alkoxy group having 1 to 4 carbon atoms.
炭素原子数 2〜 6個の直鎖状もしくは分枝鎖状アルケニル基とは例えばビニル基、 プ 口ぺニル基、 2 -メチル -2-ブテニル基、 1, 3-ブタジェニル基、 2, 4-ジメチル- 1 , 4-ペン夕 ジェニル基が挙げられる。  A linear or branched alkenyl group having 2 to 6 carbon atoms is, for example, a vinyl group, a propenyl group, a 2-methyl-2-butenyl group, a 1,3-butadienyl group, a 2,4- Dimethyl-1,4-pentenyl phenyl group.
炭素原子数 1〜 6個の直鎖状もしくは分枝鎖状アルキル基とは、 例えばメチル基、 ェ チル基、 イソプロピル基、 n-プロピル基、 n -ブチル基、 t -ブチル基、 へキシル基が挙 げられる。  A linear or branched alkyl group having 1 to 6 carbon atoms is, for example, a methyl group, an ethyl group, an isopropyl group, an n-propyl group, an n-butyl group, a t-butyl group, a hexyl group Are listed.
置換もしくは無置換の炭素原子数 3〜 1 0個のシクロアルキル基とは例えばシク口プ 口ピル基、 シクロブチル基、 シクロペンチル基、 2, 4-ジメチルシクロペンチル基、 シク 口へキシル基、 2-メチルシクロへキシル基、 4_イソプチルシクロへキシル基、 シクロへ プチル基、 3-クロ口- 4-メトキシシク口へプチル基、 4-ブトキシシクロォクチル基が挙 げられる。 シクロアルキル基における置換基とは、 反応に関与しなければ特に限定はされないがA substituted or unsubstituted cycloalkyl group having 3 to 10 carbon atoms is, for example, a cycl group, a cyclobutyl group, a cyclopentyl group, a 2,4-dimethylcyclopentyl group, a cyclohexyl group, a 2-methylcyclo group. Hexyl, 4-isobutylcyclohexyl, cycloheptyl, 3-chloro-4-methoxycycloheptyl, and 4-butoxycyclooctyl. The substituent in the cycloalkyl group is not particularly limited as long as it does not participate in the reaction.
、 例えば八ロゲン原子、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルキル基及び 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルコキシ基の群から選ばれる一つもし くは複数の基が挙げられる。 For example, one selected from the group consisting of octylogen atoms, linear or branched alkyl groups having 1 to 4 carbon atoms, and linear or branched alkoxy groups having 1 to 4 carbon atoms. Or more than one group.
置換もしくは無置換のフエニル基とは例えばフエニル基、 4-ブロモフエニル基、 2 -メ チル -4-メトキシフエニル基が挙げられる。  Examples of the substituted or unsubstituted phenyl group include a phenyl group, a 4-bromophenyl group, and a 2-methyl-4-methoxyphenyl group.
フエニル基における置換基とは、 反応に関与しなければ特に限定はされないが、 例え ばハロゲン原子、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルキル基及び炭素原 子数 1〜 4個の直鎖状もしくは分枝鎖状アルコキシ基の群から選ばれる一つもしくは複 数の基が挙げられる。  The substituent in the phenyl group is not particularly limited as long as it does not participate in the reaction.Examples include a halogen atom, a linear or branched alkyl group having 1 to 4 carbon atoms, and a carbon atom having 1 to 4 carbon atoms. One or more groups selected from the group of four linear or branched alkoxy groups.
置換もしくは無置換のフエノキシ基とは例えばフエノキシ基、 2-メチルフエノキシ基 、 2-クロロフエノキシ基、 4 -イソプロポキシフエノキシ基が挙げられる。  Examples of the substituted or unsubstituted phenoxy group include a phenoxy group, a 2-methylphenoxy group, a 2-chlorophenoxy group, and a 4-isopropoxyphenoxy group.
フエノキシ基における置換基とは、 反応に関与しなければ特に限定はされないが、 例 えばハロゲン原子、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルキル基及び炭素 原子数 1〜 4個の直鎖状もしくは分枝鎖状アルコキシ基の群から選ばれる一つもしくは 複数の基が挙げられる。  The substituent in the phenoxy group is not particularly limited as long as it does not participate in the reaction.Examples include a halogen atom, a linear or branched alkyl group having 1 to 4 carbon atoms, and a carbon atom having 1 to 4 carbon atoms. And one or more groups selected from the group consisting of a single linear or branched alkoxy group.
置換もしくは無置換の炭素原子数 3〜 1 0個のシクロアルキルォキシ基とは例えば 2_ メチルシクロへキシルォキシ基、 3 -プロモシク口へプチルォキシ基が挙げられる。  Examples of the substituted or unsubstituted cycloalkyloxy group having 3 to 10 carbon atoms include a 2-methylcyclohexyloxy group and a 3-bromooxyheptyloxy group.
シクロアルキルォキシ基における置換基とは、 反応に関与しなければ特に限定はされ ないが、 例えば八ロゲン原子、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルキル 基及び炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルコキシ基の群から選ばれる一 つもしくは複数の基が挙げられる。  The substituent in the cycloalkyloxy group is not particularly limited as long as it does not take part in the reaction. Examples thereof include an octogen atom, a linear or branched alkyl group having 1 to 4 carbon atoms, and a carbon atom. One or a plurality of groups selected from the group of linear or branched alkoxy groups having a number of 1 to 4 are exemplified.
力ルポキシル基の保護基とは、 各反応において保護基として働く基であればよく、 例 えば炭素原子数 1〜 6個の直鎖状もしくは分枝鎖状アルキル基、 ベンジル基、 置換ベン ジル基、 ジフエ二ルメチル基、 メトキシメチル基、 トリクロ口ェチル基、 トリェチルシ リル基、 t -プチルジメチルシリル基、 2 -(卜リメチリレシリル)ェチル基、ァリル基が挙げ られる。  The protecting group for the lipoxyl group may be any group that functions as a protecting group in each reaction, for example, a linear or branched alkyl group having 1 to 6 carbon atoms, a benzyl group, a substituted benzyl group. And diphenylmethyl group, methoxymethyl group, trichloroethyl group, triethylsilyl group, t-butyldimethylsilyl group, 2- (trimethylylsilyl) ethyl group, and aryl group.
置換べンジル基とは、 反応に関与しなければ特に限定はされないが、 例えば八ロゲン 原子、 炭素原子数 1〜 4個の直鎖状もしくは分枝鎖状アルキル基及び炭素原子数 1〜 4 個の直鎖状もしくは分枝鎖状アルコキシ基の群から選ばれる一つもしくは複数の基をべ ンゼン環上の置換基として有している基であればよく、 例えば 4-クロ口べンジル基、 2, 6 -ジメチルペンジル基、 2 -ブロモ -4 -メチルベンジル基が挙げられる。 The substituted benzyl group is not particularly limited as long as it does not participate in the reaction. One or more groups selected from the group consisting of a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms and a straight-chain or branched-chain alkoxy group having 1 to 4 carbon atoms. Any group may be used as long as it is a substituent on the benzene ring, and examples thereof include 4-chlorobenzyl, 2,6-dimethylpentyl, and 2-bromo-4-methylbenzyl.
水酸基の保護基とは、 各反応において保護基として働く基であればよく、 トリアルキ ルシリル基、 アルコキシアルキル基、 ァラルキルォキシアルキル基、 トリチル基または テトラヒドロピラニル (THP)基などが挙げられ、 例えばトリメチルシリル基、 トリェチ ルシリル基、 t -プチルジメチルシリル基、 メトキシメチル基、 ベンジルォキシメチル基 、 ァセチル基、 ベンゾィル基、 ベンジル基、 P-メトキシベンジル基、 p -二卜口べンジル 基、 トリ(P-メトキシフエ二ル)メチル基、 ベンジルォキシカルボニル基が挙げられる。 チオール基の保護基とは、 各反応において保護基として働く基であればよく、 例えば ベンジル基、 4 -メトキシベンジル基、 ジフエニルメチル基、 卜リチル基、 メトキシメチ ル基、 ベンジルォキシカルボニル基が挙げられる。  The hydroxyl-protecting group may be any group that functions as a protecting group in each reaction, and includes a trialkylsilyl group, an alkoxyalkyl group, an aralkyloxyalkyl group, a trityl group or a tetrahydropyranyl (THP) group. For example, trimethylsilyl group, triethylsilyl group, t-butyldimethylsilyl group, methoxymethyl group, benzyloxymethyl group, acetyl group, benzoyl group, benzyl group, P-methoxybenzyl group, p-methoxybenzyl group, And a tri (P-methoxyphenyl) methyl group and a benzyloxycarbonyl group. The protecting group for the thiol group may be any group that functions as a protecting group in each reaction, and examples thereof include a benzyl group, a 4-methoxybenzyl group, a diphenylmethyl group, a trityl group, a methoxymethyl group, and a benzyloxycarbonyl group. .
トリアルキルシリルトリフラートとは、 例えば t -プチルジメチルシリルトリフラート トリアルキルシリル基とは、 例えばトリメチルシリル基、 t -プチルジメチルシリル基 、 トリェチルシリル基が挙げられる。  The trialkylsilyl triflate includes, for example, t-butyldimethylsilyl triflate. The trialkylsilyl group includes, for example, a trimethylsilyl group, a t-butyldimethylsilyl group, and a triethylsilyl group.
酸とは鉱酸、 有機酸及びルイス酸等が挙げられ、 さらに詳しくは鉱酸とは、 例えば塩 化水素の有機溶媒溶液、 濃硫酸、 リン酸が挙げられる。  The acid includes a mineral acid, an organic acid, a Lewis acid, and the like. More specifically, the mineral acid includes, for example, an organic solvent solution of hydrogen chloride, concentrated sulfuric acid, and phosphoric acid.
有機酸とは、 例えばトリフルォロ酢酸、 ベンゼンスルホン酸、 P-トルエンスルホン酸、 メタンスルホン酸、 ドデシルべンゼンスルホン酸が挙げられる。 Examples of the organic acid include trifluoroacetic acid, benzenesulfonic acid, P-toluenesulfonic acid, methanesulfonic acid, and dodecylbenzene sulfonic acid.
ルイス酸とは、 例えば塩化チタン(IV)、塩化亜鉛、臭化亜鉛、 トリフルォロメタンスルホ ン酸亜鉛、 過塩素酸マグネシウム、 トリフルォロメ夕ンスルホン酸マグネシウム、 三弗 化ホウ素ジェチルェ一テル錯体、 塩化アルミニウム(111)、 塩化ジェチルアルミニウム が挙げられる。 発明を実施するための最良の形態 以下、 本発明をより詳細に説明するが、 例示されたものに特に限定はされない。 Lewis acids include, for example, titanium (IV) chloride, zinc chloride, zinc bromide, zinc trifluoromethanesulfonate, magnesium perchlorate, magnesium trifluoromethanesulfonate, boron trifluoride-ethyl chloride complex, aluminum chloride ( 111) and getyl aluminum chloride. BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in more detail, but is not particularly limited to those exemplified.
式 [I]の化合物は、 例えば特許第 2570796号、 Eur. J. Org. Chem.1999, 2655- 2662等に記載 された方法に準拠し、 製造することができる。 The compound of the formula [I] can be produced, for example, according to the method described in Patent No. 2570796, Eur. J. Org. Chem. 1999, 265-2662, and the like.
また式 [III]の化合物については、 通常の有機金属試薬の調製法に準拠して調製するこ とができる。 例えば式 [III]の有機亜鉛試薬 (Mは BrZn) を調製する場合には、 まず活性 亜鉛と 1, 2-ジブロモエタンをテトラヒドロフラン中加熱し、 臭化亜鉛 (ZnBr2) のテト ラヒドロフラン溶液を調製し、 これを別途調製した式 [III]' » 二 (メ CHI] で表わされるリチウム塩に加えることにより調製することができる。 この方法において は臭化亜鉛の使用量はリチウム塩に対して、 0.5〜2当量、 好ましくは 0.8〜1.2当量が良 い。 In addition, the compound of the formula [III] can be prepared according to a usual method for preparing an organometallic reagent. For example, when preparing an organozinc reagent of the formula [III] (M is BrZn), first heat active zinc and 1,2-dibromoethane in tetrahydrofuran to prepare a tetrahydrofuran solution of zinc bromide (ZnBr 2 ). Then, it can be prepared by adding it to a separately prepared lithium salt represented by the formula [III] '»ii (CHI). In this method, the amount of zinc bromide used is 0.5 to 2 equivalents, preferably 0.8 to 1.2 equivalents are good.
有機アルミニウムアート錯体は、 上記と同様に調製した式 [III]'のリチウム塩にトリ アルキルアルミニウム (A1R8 3) を加えて調製することができる。 この方法においては トリアルキルアルミニウムの使用量はリチウム塩に対して, 0.5〜2当量、 好ましくは 0.8〜1.2当量が良い。 式 [ΠΙ]の化合物の調製に使用する溶媒に特に限定はなく、 反応 を阻害しないものであればよく、 例えばテトラヒドロフラン、 ジェチルェ一テル、 シク 口ペンチルメチルエーテル、 トルエン、 へキサンが挙げられる。 Organoaluminum ate complex can be prepared by adding trialkylaluminum (A1R 8 3) the lithium salt of the formula was prepared in the same manner as described above [III] '. In this method, the amount of the trialkylaluminum used is 0.5 to 2 equivalents, preferably 0.8 to 1.2 equivalents, relative to the lithium salt. The solvent used for the preparation of the compound of the formula [II] is not particularly limited and may be any solvent which does not inhibit the reaction, and examples thereof include tetrahydrofuran, geethylether, cyclopentyl methyl ether, toluene and hexane.
式 [IV]の化合物は、 例えば以下の方法により製造できる。  The compound of the formula [IV] can be produced, for example, by the following method.
式 [I]の化合物と式 [111]の有機亜鉛試薬 (Mは BrZn) との反応においては、 式 [I]の 化合物に対して、 トリアルキルシリルトリフラートを 0.5〜5当量、 好ましくは 0.8〜3当 量、 式 [III]の有機亜鉛試薬は式 [I]の化合物に対して、 0.5〜5当量、 好ましくは 0.8〜3 当量用いる場合が良い。 反応温度は _100〜50°C、 好ましくは- 80〜30°Cであり、 反応時 間は通常 5分〜 50時間である。 一方、 式 [I]の化合物と式 [III]の有機アルミニウムァー ト錯体 (Mは LiR8 3Al) との反応においては、 式 [I]の化合物に対して、 トリアルキルシ リルトリフラートを 0.5〜3当量、 好ましくは 0.8〜2当量、 式 [III]の有機アルミニウム ァート錯体は式 [I]の化合物に対して、 0.5〜4当量、 好ましくは 0.8~2当量用いる場合 が良い。 反応温度は- 100〜20°C、 好ましくは _80〜0°Cであり、 反応時間は通常 5分〜 5 時間である。 これらの反応で用いる溶媒に特に限定はなく、 反応を阻害しないものであ ればよく、 例えばテトラヒドロフラン、 ジェチルエーテル、 シクロペンチルメチルエー テル、 へキサン、 トルエンが挙げられる。 In the reaction of the compound of the formula [I] with the organozinc reagent of the formula [111] (M is BrZn), the trialkylsilyl triflate is added to the compound of the formula [I] in an amount of 0.5 to 5 equivalents, preferably 0.8 to 5 equivalents. The organic zinc reagent of the formula [III] is used in an amount of 0.5 to 5 equivalents, preferably 0.8 to 3 equivalents to the compound of the formula [I]. The reaction temperature is -100 to 50 ° C, preferably -80 to 30 ° C, and the reaction time is usually 5 minutes to 50 hours. On the other hand, with respect to the compound of formula in the reaction of the organoaluminum § over preparative complex of a compound of [I] and formula [III] (M is LiR 8 3 Al), the formula [I], 0.5 to the Toriarukirushi Lil triflate 3 equivalents, preferably 0.8 to 2 equivalents, when the organoaluminate complex of the formula [III] is used in an amount of 0.5 to 4 equivalents, preferably 0.8 to 2 equivalents to the compound of the formula [I] Is good. The reaction temperature is -100 to 20 ° C, preferably _80 to 0 ° C, and the reaction time is usually 5 minutes to 5 hours. The solvent used in these reactions is not particularly limited as long as it does not inhibit the reaction, and examples thereof include tetrahydrofuran, getyl ether, cyclopentylmethyl ether, hexane, and toluene.
上記の式 [I]の化合物と式 [I I I]の有機亜鉛試薬 (Mは BrZn) 、 または式 [I I I]の有機ァ ルミニゥムアート錯体 (Mは LiR8 3Al) との反応において、 ]3位の置換ェチニル基側鎖は ァ位の保護された水酸基に対し、 高立体選択的にトランス配置に導入される。 特に、 式 [I I I]で表わされる化合物中で R3がシクロへキシル基、 Zが Z'R4の場合で Z'が酸素原子、 Rが t_プチルジメチルシリル基の場合に極めて高い立体選択性が得られた。 In the reaction with organic § Ruminiumuato complex (M is LiR 8 3 Al) compounds and organozinc reagent of formula [III] of the formula [I] (M is BrZn), or Formula [III],] 3-position of The substituted ethynyl group side chain is introduced into the trans configuration in a highly stereoselective manner to the protected hydroxyl group at the α-position. In particular, in the compound represented by the formula [III], when R 3 is a cyclohexyl group, Z is Z′R 4 , Z ′ is an oxygen atom, and R is a t_butyldimethylsilyl group, a very high stereoselectivity Sex was obtained.
式 [V]の化合物は、 例えば以下の方法、 即ち式 [IV]の化合物に非水条件下、 酸を作用 させる方法により製造できる。 酸としては、 鉱酸、 有機酸、 またはルイス酸などが挙げ られ、 好ましくは、 ベンゼンスルホン酸、 P-トルエンスルホン酸、 メタンスルホン酸、 過塩素酸マグネシゥムなどである。 酸の使用量は式 [IV]の化合物に対して、 0. 5〜3当 量、 好ましくは 1〜2当量用いる場合が良い。 反応温度は- 100〜50°C、 好ましくは- 80〜 30Όであり、 反応時間は通常 0. 5〜20時間である。 この反応で用いる溶媒に特に限定は なく、 反応を阻害しないものであればよく、 例えばテトラヒドロフラン、 ジェチルエー テル、 ジクロロメタン、 クロ口ホルム、 トルエン., ァセトニトリルが挙げられる。  The compound of the formula [V] can be produced, for example, by the following method, that is, a method of reacting a compound of the formula [IV] with an acid under non-aqueous conditions. Examples of the acid include a mineral acid, an organic acid, and a Lewis acid, and preferably include benzenesulfonic acid, P-toluenesulfonic acid, methanesulfonic acid, and magnesium perchlorate. The acid is used in an amount of 0.5 to 3 equivalents, preferably 1 to 2 equivalents, to the compound of the formula [IV]. The reaction temperature is −100 to 50 ° C., preferably −80 to 30 ° C., and the reaction time is usually 0.5 to 20 hours. The solvent used in this reaction is not particularly limited as long as it does not inhibit the reaction, and examples include tetrahydrofuran, getyl ether, dichloromethane, chloroform, toluene, and acetonitrile.
上記の脱トリアルキルシリル化反応において、 側鎖は β側鎖に対して高立体選択的 にトランス配置に誘導される。  In the above detrialkylsilylation reaction, the side chain is highly stereoselectively induced in the trans configuration with respect to the β side chain.
また、 本発明の他の実施の形態は、 式 [I]の化合物と式 [111]の有機金属試薬とを 1当 量以上のトリアルキルシリルトリフラートの存在下で反応させることにより式 [IV]の化 合物を単離することなく、 一挙に式 [V]の化合物を得る製造法である。  In another embodiment of the present invention, a compound of the formula [IV] is reacted with a compound of the formula [I] and an organometallic reagent of the formula [111] in the presence of one or more equivalents of a trialkylsilyl triflate. This is a process for obtaining a compound of the formula [V] at a stroke without isolating the compound of formula (I).
ここでいう 1当量以上とは、 トリアルキルシリルトリフラートが式 [I I I]の有機金属 試薬に対して 1〜3当量、 好ましくは 1. 5〜2. 5当量を示す。  The term “1 equivalent or more” as used herein means that the trialkylsilyl triflate is 1 to 3 equivalents, preferably 1.5 to 2.5 equivalents, based on the organometallic reagent of the formula [III].
例えばトリアルキルシリルトリフラー卜として t -プチルジメチルシリルトリフラート を用いる場合には、 式 [I]の化合物に対して式 [I I I]の有機亜鉛試薬 (Mは BrZn) の使用 量は 0. 8〜2当量、 好ましくは 1〜1. 5当量、 また卜プチルジメチルシリルトリフラー卜の 使用量は式 [I I I]の有機亜鉛試薬 (Mは BrZn) に対して、 1〜3当量、 好ましくは 1. 5〜2. 5 当量用いる場合が良い。 反応温度は- 100 50°C、 好ましくは- 80 30°Cであり、 反応時 間は通常 1 50時間である。 この反応で用いる溶媒に特に限定はなく、 反応を阻害しな いものであればよく、 例えばテトラヒドロフラン、 ジェチルエーテル、 シクロペンチル メチルエーテル、 へキサン、 トルエンが挙げられる。 For example, when t-butyldimethylsilyl triflate is used as the trialkylsilyl triflate, the amount of the organozinc reagent of the formula [III] (M is BrZn) to the compound of the formula [I] is 0.8 to 2 equivalents, preferably 1 to 1.5 equivalents, and the amount of topyldimethylsilyl triflate used is 1 to 3 equivalents, preferably 1., based on the organozinc reagent of the formula [III] (M is BrZn). 5-2.5 It is better to use the equivalent. The reaction temperature is −100 to 50 ° C., preferably −80 to 30 ° C., and the reaction time is usually 150 hours. The solvent used in this reaction is not particularly limited as long as it does not inhibit the reaction, and examples thereof include tetrahydrofuran, getyl ether, cyclopentyl methyl ether, hexane, and toluene.
さらに、 実施例及び従来法との比較例により本発明を説明する。  Further, the present invention will be described with reference to Examples and Comparative Examples with the conventional method.
1) 本発明を利用し、 強力な生理活性を有する 13 14-ジデヒドロプロスタグランジン E誘導体を毒物を用いることなく安全に、 好収率、 高立体選択的、 且つ工業的有利に製 造することができた。  1) By utilizing the present invention, a 1314-didehydroprostaglandin E derivative having a strong physiological activity can be produced safely without using toxic substances, in high yield, high stereoselectivity, and industrially advantageous. I was able to.
以下に実施例を挙げて本発明をより具体的に説明するが、 本発明は下記実施例に限定 されるものではない。 下記例において、 THFはテトラヒドロフラン、 Meはメチル基、 TBS は t -ブチルジメチルシリル基、 TESはトリェチルシリル基、 HPLCは高速液体クロマトグ ラフィーを表わす。 実施例  Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to the following examples. In the following examples, THF represents tetrahydrofuran, Me represents a methyl group, TBS represents a t-butyldimethylsilyl group, TES represents a triethylsilyl group, and HPLC represents high-performance liquid chromatography. Example
Figure imgf000016_0001
Figure imgf000016_0001
化合物 4 (0.23g,0.81mmol)をジェチルェ一テル(3.2mL)に溶解させ、 アルゴン雰囲気 下 - 10°Cで n-ブチルリチウム (1.57M, n -へキサン溶液, 0.51mL, 0.80匪 ol)を滴下し、 20分 間攪拌した。 さらに- 78°Cに冷却後、 トリメチルアルミニウム(Ι.ΟΟΜ,η-へキサン溶液, 0.81mL 0.81腿 ol)を滴下し 30分間攪拌した。 これに化合物 1 (0.20g, 0.54龍 ol)のジェチ ルエーテル(1.6mL)溶液を加え、 次いで t-ブチルジメチルシリルトリフラート (0.18g, 0.69I O1)のジェチルェ一テル(1.6mL)溶液を加えた。 同温度で 1時間攪拌後、 飽和炭酸 力リゥム水溶液を加え、 ジェチルエーテルで抽出し、有機層を無水硫酸マグネシウムで 乾燥後、 減圧濃縮した。 残渣 (HPLCより化合物 2 :化合物 3=144 : 1) をシリカゲル力 ラムクロマトグラフィー (溶出溶媒; n-へキサン:酢酸ェチル =20: 1)に付し、 化合物 ·(Compound 4 (0.23 g, 0.81 mmol) was dissolved in geethyl ether (3.2 mL) and n-butyllithium (1.57 M, n-hexane solution, 0.51 mL, 0.80 ol) was used at -10 ° C under an argon atmosphere. Was added dropwise and stirred for 20 minutes. After further cooling to −78 ° C., trimethylaluminum (Ι.ΟΟΜ, η-hexane solution, 0.81 mL 0.81 liter) was added dropwise and stirred for 30 minutes. To this was added a solution of compound 1 (0.20 g, 0.54 dragonol) in ethyl ether (1.6 mL), followed by a solution of t-butyldimethylsilyl triflate (0.18 g, 0.69I O1) in dimethyl ether (1.6 mL). . After stirring at the same temperature for 1 hour, a saturated aqueous solution of carbon dioxide was added, extracted with getyl ether, the organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue (compound 2: compound 3 = 144: 1 by HPLC) was subjected to silica gel column chromatography (elution solvent: n-hexane: ethyl acetate = 20: 1) to give the compound · (
HI ' ) 82 - ' (Ηΐ 'ιπ) 80 ' ' (HC ' fL "g ' (HZ ' II "8 ' (HZ Ά=ί Ί) S9 'I ' (HI ¾)89 'Z-99 ' ' (IK £ui) L 18 ΐ ·1 ' (Η8ΐ ' 90 — 8S ·Γ (H9 ' ) 82 Ί-δ6 ·0 ' (Η6 'δ) 26 ·0 ' (Η6 'δ) 06 ·0 ' (Η6 's) 68 ·0 ' (Η9 's) Ζ ΓΟ ' (Η9 's) ΟΓΟ ' (HS ' 80 ·0 ' (HC 'δ) 10 ·0 :π Μ ρ (Zffi¾OOZ ' 3(D)丽- Η , HI ') 82-' (Ηΐ 'ιπ) 80''(HC' fL "g '(HZ'II" 8 '(HZ Ά = ί Ί) S9' I '(HI ¾) 89' Z-99 '' (IK £ ui) L 18 ΐ · 1 '(Η8ΐ' 90 — 8S · Γ (H9 ') 82 Ί-δ6 · 0' (Η6 'δ) 26 · 0' (Η6 'δ) 06 · 0' (Η6 's) 680'(Η9's) Ζ ΓΟ '(Η9's) ΟΓΟ' (HS '80 · 0 '(HC' δ) 10 · 0: π Μ ρ (Zffi¾OOZ '3 (D) 丽- Η,
°¾ ¾ (%ο ·Ζ8« 'su 'm ° ¾ ¾ (% ο · Ζ8 «'su' m
) S 、つ 二 Κΐ : ΟΖ=Λ(^ΜΜ: ^φ -ιι:翁 ロ^マ ) S, two Κΐ: ΟΖ = Λ (^ ΜΜ: ^ φ -ιι: Okina Roma
°¾っ纖蕭 30 翁 ¾
Figure imgf000017_0001
、¥ ¾澳缀氺マ η 哪 翻 τ ^m m °^w m (™ ·8) ^—ェ ^ェ ω ( 丽 ·ε
° Pot Fiber Xiao 30 Okina ¾
Figure imgf000017_0001
, ¥ ¾ao 缀 氺 ma η 翻 τ ^ mm ° ^ wm (™ · 8) ^ — ェ ^ ェ ω (丽 · ε
'§98 ·0) 4—
Figure imgf000017_0002
逖缪 C 0 ·8)4ί ーェ ェ (10匪 89 'I '§00 Ί) I ^ コ °¾つ 1¾ ^0Sつ丄纖 (10画 ' S0
Figure imgf000017_0003
'§98 · 0) 4—
Figure imgf000017_0002
缪 缪 C 0 · 8) 4 ί 10 (10 maraud 89 'I' §00 Ί) I ^ コ ° 1 ¾ ^ 0 S 丄 Fiber (10 strokes' S0
Figure imgf000017_0003
i、つ土继¾ (1。丽 so · £TO 'I '¾¾ -fr÷ -u ' ·ΐ)マ fi - u^C H -丄 Μ Ρ ( ^^m ^ (Ίιι'0 ·9Ι) 一ェ ェ (louuneo 't '§Ζ0 Ί) Ζ f ^^J- i, tsuto (1. 丽 so · £ TO 'I' ¾¾ -fr ÷ -u '· ΐ) ma fi-u ^ CH-丄 Μ ^ (^^ m ^ (Ί ιι ' 0 · 9Ι) One (louuneo 't' §Ζ0 Ί) Ζ f ^^ J-
Figure imgf000017_0004
Figure imgf000017_0004
• (HI -9-30 ·3 ' (Ηΐ ' 9 'ΐ '0 Ά=ί 'WZf 1 (Ηΐ 'ZHS ' 'Z ·Ζ=ί 'WLZ'f (HS 's) L '8 ' (HZ 's) I S ' (HI 12 ·2_6ΐ '8 ' (HS 09 'Z-09 'I ' (HZ 'ω) II -ίΙ 'I ' (H8 90 ·Ζ- 06 T(HS 's)89 'ΐ '(Η8 's)09 T (Η8Ϊ ¾) 62, · 1-80 T(H6 's) 26 ·0 ' (H6 '§) 68 ·0 ' (HS 'ω) 16 ·0 - 8 ·0 ' (Η8Ι ¾)2ΐ ·0 - Α0 ·0 : (1 ρ (¾ )0S ' SI»漏- Η , • (HI -9-30 · 3 '(Ηΐ' 9 'ΐ' 0 Ά = ί 'WZf 1 (Ηΐ' ZHS '' Z · Ζ = ί 'WLZ'f (HS' s) L '8' (HZ 's) IS' (HI 122_6ΐ '8' (HS 09 'Z-09' I '(HZ' ω) II -ίΙ 'I' (H8 90 · Ζ- 06 T (HS 's) 89' ΐ '(Η8' s) 09 T (Η8Ϊ ¾) 62, 1-80 T (H6 's) 26 · 0' (H6 '§) 6800' (HS 'ω) 16 · 0-8 (Η8Ι ¾) 2ΐ · 0-Α0 · 0: (1 ρ (¾) 0S ' S I »leakage Η,
°¾ ¾ (¾8 ·69傘 '§62 ·0 '呦^ Ζ ° ¾ ¾ (¾8 · 69 umbrella '§62 · 0' 呦 ^ Ζ
Figure imgf000018_0001
Figure imgf000018_0001
化合物 1 1 (0.20g, 2.04皿 ol)を THF(4.8mL)に溶解させ、 アルゴン雰囲気下— 10°Cで n_ ,プチルリチウム (1.57M, n -へキサン溶液, 1. 8mL, 2.01腿 ol)を滴下し、 20分間攪拌した。 さらに - 78°Cに冷却後、 トリメチルアルミニウム(1.00M, n -へキサン溶液, 2. OlmL, 2.01 讓 ol)を滴下し 30分間攪拌した。 これに化合物 8 (0.30g,0.81mmol)のジェチルエーテル( 2. mL)溶液を加え、 次いで t-ブチルジメチルシリル卜リフラ一ト(0.43g, 1.63腿 ol)のジ ェチルエーテル (2.4mL)溶液を加えた。 同温度で 1時間攪拌後、 飽和炭酸カリウム水溶 液を加え、 ジェチルエーテルで抽出し、 有機層を無水硫酸マグネシウムで乾燥後、 減圧 濃縮した。 残渣 (HPLCより化合物 9 :化合物 10=75: 1)をシリカゲルカラムクロマト グラフィー (溶出溶媒; n-へキサン:ジェチルエーテル =20: 1)に付し、 化合物 9 (油 状物, 0.37g,収率 78.0%)を得た。  Compound 11 (0.20 g, 2.04 dishes ol) was dissolved in THF (4.8 mL), and n-, butyllithium (1.57 M, n-hexane solution, 1.8 mL, 2.01 tol) was dissolved in an argon atmosphere at −10 ° C. ) Was added dropwise and stirred for 20 minutes. After further cooling to -78 ° C, trimethylaluminum (1.00 M, n-hexane solution, 2. OlmL, 2.01 benzene) was added dropwise and stirred for 30 minutes. To this was added a solution of compound 8 (0.30 g, 0.81 mmol) in dimethyl ether (2 mL), followed by a solution of t-butyldimethylsilyl triflate (0.43 g, 1.63 liter) in dimethyl ether (2.4 mL). Was added. After stirring at the same temperature for 1 hour, a saturated aqueous solution of potassium carbonate was added, extracted with getyl ether, and the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue (compound 9: compound 10 = 75: 1 by HPLC) was subjected to silica gel column chromatography (elution solvent: n-hexane: getyl ether = 20: 1) to give compound 9 (oil, 0.37 g, Yield 78.0%).
1 H-NMR(CDC13 , 300MHz) δ ppm;0.09 (s, 3H) , 0.10(s, 3H), 0.11 (s, 3H) ,0.12(s, 3H) , 0.84— 0.98 (m, 3H), 0.89 (s, 9H) , 0.93 (s,9H), 1.18-1.70 (m, 12H),2.10-2.28 (m, 3H), 2.46-2.66 (m, 3H) , 3.14-3.22 (m, 1H) , 3.22 (s, 2H) , 3.73 (s, 3H) , 4.22-4.30 (m, 1H) . 実施例 4 1 H-NMR (CDC1 3, 300MHz) δ ppm; 0.09 (s, 3H), 0.10 (s, 3H), 0.11 (s, 3H), 0.12 (s, 3H), 0.84- 0.98 (m, 3H), 0.89 (s, 9H), 0.93 (s, 9H), 1.18-1.70 (m, 12H), 2.10-2.28 (m, 3H), 2.46-2.66 (m, 3H), 3.14-3.22 (m, 1H), 3.22 (s, 2H), 3.73 (s, 3H), 4.22-4.30 (m, 1H).
Figure imgf000018_0002
Figure imgf000018_0002
12 ★:相対配置を示す 化合物 7 (1.70g,6.7lMiol)をジェチルェ一テル(6.8mL)に溶解し、 アルゴン雰囲気下 _40°Cで n-ブチルリチウム (1.37M, n-へキサン溶液, .90mL, 6.71腿 ol)を加え、 15分間攪 拌後、 同温度で臭ィ匕亜鉛(1.0M,THF溶液, 6.70mL,6.70腿 ol)を加え、 室温で 10分間攪拌し た。 再び- 40°Cに冷却し、 化合物 8 (1.0(^,2.69腿01)のジェチルェーテル(4.0 )溶液、 t -プチルジメチルシリルトリフラート(1.54mL, 6.70醒 ol)を加え、 同温度で 30分間、 0°C で 1時間、 室温で 4時間攪拌した。 反応液に飽和炭酸水素ナトリウム水溶液を加え、 ジ ェチルエーテルで抽出し、 有機層を水洗し、 無水硫酸マグネシウムで乾燥後、 減圧濃縮 した。 残渣をシリカゲルカラムクロマトグラフィー (溶出溶媒; n -へキサン:酢酸ェチ ル =100: 1→5: 1)に付し、 化合物 1 2 (油状物, 1.73g,収率 87.2%)を得た。 12 ★: Compound 7 (1.70 g, 6.7 lMiol) showing relative configuration was dissolved in geethylether (6.8 mL), and n-butyllithium (1.37 M, n-hexane solution, -40 ° C) was dissolved in an argon atmosphere at _40 ° C. 90 mL, 6.71 t), add 15 minutes of stirring, add zinc chloride (1.0 M, THF solution, 6.70 mL, 6.70 t) at the same temperature, and stir at room temperature for 10 minutes. Was. After cooling to -40 ° C again, compound 8 (1.0 (^, 2.69 thigh 01) in getyl ether (4.0) solution, t-butyldimethylsilyl triflate (1.54 mL, 6.70 liters) was added, and the mixture was added at the same temperature for 30 minutes. The mixture was stirred for 1 hour at 0 ° C. and for 4 hours at room temperature A saturated aqueous solution of sodium hydrogencarbonate was added to the reaction solution, extracted with diethyl ether, the organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (elution solvent; n-hexane: ethyl acetate = 100: 1 → 5: 1) to obtain Compound 12 (oil, 1.73 g, yield 87.2%).
1 H-NMR(CDC13, 200MHz) δ ppm;0.07 (s, 3H) , 0.08 (s, 3H) , 0.10 (s, 6H) , 0.12 (s, 6H) , 0.89 (s, 9H) , 0.90 (s, 9H) , 0.93 (s, 9H) , 0.93—1.28 (m, 8H), 1.38-2.05 (m, 9H),2.18- 2.27 (m, 2H) , 2.56-2.58 (m, 1H) , 2.63 (t, J=7.0Hz, 2H), 3.22 (s, 2H) , 3.74 (s, 3H) , 4.08 (m, 1H), 4.28 (m, 1H) 1 H-NMR (CDC1 3, 200MHz) δ ppm; 0.07 (s, 3H), 0.08 (s, 3H), 0.10 (s, 6H), 0.12 (s, 6H), 0.89 (s, 9H), 0.90 ( s, 9H), 0.93 (s, 9H), 0.93-1.28 (m, 8H), 1.38-2.05 (m, 9H), 2.18- 2.27 (m, 2H), 2.56-2.58 (m, 1H), 2.63 ( t, J = 7.0Hz, 2H), 3.22 (s, 2H), 3.74 (s, 3H), 4.08 (m, 1H), 4.28 (m, 1H)
実施例 5 Example 5
Figure imgf000019_0001
Figure imgf000019_0001
化合物 7 (0.85g, 3.35mraol)をジェチルェ一テル(3· 4mL)に溶角早し、 アルゴン雰囲気下 - 40でで n-プチルリチウム (1.37M, n -へキサン溶液, 2.45mL, 3.36腿 ol)を加え、 15分間攪 拌後、 同温度で臭化亜鉛(1.0M, THF溶液, 3.35mL, 3.35mmol)を加え、 室温で 10分間した。 再び- 40°Cまで冷却し、 化合物 1 (0.50g, 1.34匪 ol)のジェチルエーテル(2. OmL)溶液、 ト リェチルシリルトリフラ一ト (0.76mL, 3.36墮 ol)を加え、 同温度で 30分間、 0。Cで 1時間 、 室温で 17時間攪拌した。 反応液に飽和炭酸水素ナトリウム水溶液を加え、 ジェチルェ 一テルで抽出し、 有機層を水洗し、 無水硫酸マグネシウムで乾燥後、 減圧濃縮した。 残 渣をシリカゲルカラムクロマトグラフィー (溶出溶媒; n-へキサン:酢酸ェチル =100: 1→ 5: 1)に付し、 化合物 1 3 (油状物, 0.79g,収率 79.1%)を得た。  Compound 7 (0.85 g, 3.35 mraol) was rapidly dissolved in geethylether (3.4 mL), and n-butyllithium (1.37 M, n-hexane solution, 2.45 mL, 3.36 t ol) and stirred for 15 minutes, then zinc bromide (1.0 M, THF solution, 3.35 mL, 3.35 mmol) was added at the same temperature, and the mixture was stirred at room temperature for 10 minutes. The mixture was cooled again to -40 ° C, and a solution of Compound 1 (0.50 g, 1.34 ol) in getyl ether (2.OmL) and triethylsilyl triflate (0.76 mL, 3.36 inol) were added. 30 minutes at temperature 0. The mixture was stirred at room temperature for 1 hour and at room temperature for 17 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, and the mixture was extracted with diethyl ether. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (elution solvent; n-hexane: ethyl acetate = 100: 1 → 5: 1) to obtain Compound 13 (oil, 0.79 g, yield 79.1%).
1 H -丽 R(CDC13 , 200MHz) δ ppm;0.07 (s, 3H), 0.08 (s, 3H), 0.09 (s, 6H) , 0.64 (q, 1=1.8Hz, 6H) ,
Figure imgf000020_0001
剁 ^ 、 ι¾¾(ιο顧 ο ο' ο·ο)邈 伞 ^L0o L- 、つ 缀:: KWT9)く ^ロロ ¾(I0画 ' 0'§0 0) 2 T ?
Figure imgf000020_0002
1 H -丽R (CDC1 3, 200MHz) δ ppm; 0.07 (s, 3H), 0.08 (s, 3H), 0.09 (s, 6H), 0.64 (q, 1 = 1.8Hz, 6H),
Figure imgf000020_0001
剁 ^, ι¾¾ (ιο ο ο 'ο · ο) 邈 伞 ^ L0 o L-, 缀 :: KWT9) く ^ ロ (I0 drawing'0'§0 0) 2 T?
Figure imgf000020_0002
•(HI 'ui) l - -S0-S'(Hl' in) A 'ト 6S -\ ' (HI ' ·9=ί 'Β) 8Z ' (HS 's) l "g ' (H 's) ΪΖ 'S (Ht ZL 16S 'I ' (HZ U 'I -Zl T (HZ (ui) 90 - 98 ·Γ (HS 's)89 Ί'(Η8 ' 65 Ί 'O 8 -80Ί ' (Η6 's) 06 Ό ' (H6 's) 68 Ό ' (HC 's)ci ·0 '(HS's)n ·0' (H 's) 60 ·0 ' (HS 's) 80 O^dd ρ (zflWOOS 'ε 13(D)漏- H , • (HI 'ui) l--S0-S' (Hl 'in) A' G 6S-\ '(HI' 9 = ί 'Β) 8Z' (HS 's) l "g' (H 's ) ΪΖ 'S (Ht ZL 16S' I '(HZ U' I -Zl T (HZ (ui) 90-98 ・ Γ (HS 's) 89 Ί' (Η8 '65 Ί 'O 8 -80Ί' (Η6 's) 06 Ό' (H6 's) 68 Ό' (HC 's) ci · 0'(HS's) n · 0 '(H' s) 60 · 0 '(HS' s) 80 O ^ dd ρ ( zflWOOS ' ε 13 (D) leak-H,
(%z ·08雄 ' ι .o) τ (i (% z08 male 'ι.o) τ (i
:。2= ェ腳: -(+.φν-ιι :
Figure imgf000020_0003
' Γι ¾ ( I
: 2 = 腳:-(+. Φν-ιι:
Figure imgf000020_0003
'Γι ¾ (I
: 0 Z=S I : ^ T^q Q 31dH)¾¾ °¾っ鹦戳 、 翁 ¾^マ 6 ^^ A mw>m つ ^^ 氺 m ^ °¾つ 稱^く ^ロロ 氺マ: 0 Z = S I: ^ T ^ q Q 31dH) ¾¾ ° ¾ ^ 鹦 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Π 峯氺凝^ ¾靱 逖 ^
Figure imgf000020_0004
、¥1¾¾(10丽^0' 0'0)邈く
氺 氺
Figure imgf000020_0004
, ¥ 1¾¾ (10 丽 ^ 0 '0'0)
Figure imgf000020_0005
Figure imgf000020_0005
• (Ηΐ'ιπ) OS - - ' (Ηΐ ¾)601 -SO 1 ' (HS 's) l ·£ '(ΗΖ'δ)22·2£ (HZ 'ZHO =1 S9 'I ' (HI 09 ·0 - Ί ' (HZ LI -0Ζ 'I ' (H6 'ui) ΟΟ'Ζ-92'ΐ ' (H6 'z脱 ·0=ί ) 86 ·0 ' (Η8 ¾) ΖΖ ·ト S6 ·0 ' (Η6 's) 68 ·0 ' (Η6 ' 88 ·0 • (Ηΐ'ιπ) OS--'(Ηΐ ¾) 601 -SO 1' (HS 's) l · £'(ΗΖ'δ) 22 · 2 £ (HZ 'ZHO = 1 S9' I '(HI 09 0-Ί '(HZ LI -0 Ζ' I '(H6' ui) ΟΟ'Ζ-92 'ΐ' (H6 'z 脱 0 = ί) 86 860' (Η8 ¾) ΖΖ '(Η6' s) 68
6ΐ i^ o/toozdf/ェ:) d ん磨 too OAV トリウム水溶液を加え、ジクロロメタンで抽出し、 有機層を飽和食塩水で洗浄し、 無水 硫酸マグネシウムで乾燥後、 減圧濃縮した。 残渣 (HPLCより化合物 16 :化合物 17 = 71: 1)をシリカゲルカラムクロマトグラフィー (溶出溶媒; n-へキサン:酢酸ェチル = 15 : 1)に付し、化合物 16 (0.23g,収率 86.3%)を得た。 6ΐ i ^ o / toozdf / e :) d numa too OAV An aqueous thorium solution was added, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue (compound 16: compound 17 = 71: 1 by HPLC) was subjected to silica gel column chromatography (elution solvent: n-hexane: ethyl acetate = 15: 1) to give compound 16 (0.23 g, yield 86.3%). Got.
1 H-NMR(CDC13, 200MHz) δ ppm;0.08 (s, 3H) , 0.09 (s, 3H) , 0.10 (s, 3H) , 0.12 (s, 3H) , 0.89 (s, 9H) , 0.90 (s, 9H) , 0.93-1.28 (ra, 5H), 1.41-1.90 (m, 12H), 2.13-2.2 (m, 2H),2.63 (t, J-7. OHz ,2H),2.65-2.72 (m, 2H) , 3.2 (s, 2H) , 3.74 (s, 3H), 4.09 (dd, J=l.2, 2.6Hz, 1H), 4.29 (dd, J= 6.7, 13.4Hz, 1H). 実施例 8 1 H-NMR (CDC1 3, 200MHz) δ ppm; 0.08 (s, 3H), 0.09 (s, 3H), 0.10 (s, 3H), 0.12 (s, 3H), 0.89 (s, 9H), 0.90 ( s, 9H), 0.93-1.28 (ra, 5H), 1.41-1.90 (m, 12H), 2.13-2.2 (m, 2H), 2.63 (t, J-7. OHz, 2H), 2.65-2.72 (m , 2H), 3.2 (s, 2H), 3.74 (s, 3H), 4.09 (dd, J = 1.2, 2.6Hz, 1H), 4.29 (dd, J = 6.7, 13.4Hz, 1H). 8
Figure imgf000021_0001
Figure imgf000021_0001
★相対配置を示す 化合物 9 (0.20g,0.34腿 ol)をジクロロメタン(4. OiiiL)に溶解し、 - 78°Cでベンゼンスル ホン酸(0.06g,0.38mmol)を加え、 同温度で 3時間攪拌した。 反応液に飽和炭酸水素ナト リゥム水溶液を加えジクロロメタンで抽出し、 有機層を飽和食塩水で洗浄し、 無水硫酸 マグネシウムで乾燥後、 減圧濃縮した。 残渣 (HPLCより化合物 18 :化合物 19 =40: 1 )をシリカゲルカラムクロマ卜グラフィ一(溶出溶媒; n -へキサン:酢酸ェチル =20: 1 )に付し、 化合物 18 (0.130g,収率 81.3%)を得た。  ★ Dissolve compound 9 (0.20 g, 0.34 tmol) showing relative configuration in dichloromethane (4. OiiiL), add benzenesulfonic acid (0.06 g, 0.38 mmol) at -78 ° C, and at the same temperature for 3 hours Stirred. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue (compound 18: compound 19 = 40: 1 by HPLC) was subjected to silica gel column chromatography (elution solvent: n-hexane: ethyl acetate = 20: 1) to give compound 18 (0.130 g, yield 81.3). %).
1 H-NMR(CDC13 , 300MHz) <5 pm;0.10(s, 3H) , 0.13(s, 3H), 0.84-0.92 (m, 3H), 0.90 (s, 9H), 1.21-1.41 (m, 4H) , 1.42-1.82 (m, 8Η) , 2.10-2.22 (m, 4Η) , 2.60-2.71 (m, 4Η), 3.22 (s, 2H),
Figure imgf000021_0002
実施例 9
Figure imgf000022_0001
1 H-NMR (CDC1 3, 300MHz) <5 pm; 0.10 (s, 3H), 0.13 (s, 3H), 0.84-0.92 (m, 3H), 0.90 (s, 9H), 1.21-1.41 (m, 4H), 1.42-1.82 (m, 8Η), 2.10-2.22 (m, 4Η), 2.60-2.71 (m, 4Η), 3.22 (s, 2H),
Figure imgf000021_0002
Example 9
Figure imgf000022_0001
16  16
★相対配置を示す 化合物 7 (0.43 1.6811111101)をジェチルェ一テル(3.½ に溶解し、 アルゴン雰囲気下 - 40°Cで n-ブチルリチウム(1.37M,n -へキサン溶液, 1.22mL, 1.67腿 ol)を加え、 15分間攪 拌後、 同温度で臭ィ匕亜 Kl.0M,THF溶液, 1.68mL,1.68匪 ol)を加え、 室温で 10分間攪拌し た。 次いで反応液を 0°Cに冷却し、 化合物 8 (0.50g, 1.34匪 ol)のジェチルェ一テル (4.0 ml)溶液、 卜プチルジメチルシリル卜リフラ一卜 (0.77mL, 3.35nimol)を加え、 同温度で 7 時間攪拌した。反応液に飽和炭酸水素ナトリゥム水溶液を加え、 ジェチルェ一テルで抽 出し、 有機層を水洗し、 無水硫酸マグネシウムで乾燥後、 減圧濃縮した。 残渣をシリカ ゲルカラムクロマトグラフィー(溶出溶媒; n -へキサン:酢酸ェチル =100: 1→5: 1) に付し、 化合物 16 (油状物, 0.36g,収率 42.9%)を得た。  ★ Show the relative configuration Compound 7 (0.43 1.6811111101) was dissolved in Getyl ether (3.½) and n-butyllithium (1.37 M, n-hexane solution, 1.22 mL, 1.67 t ol), stirred for 15 minutes, and then added the same temperature at the same temperature, followed by stirring at room temperature for 10 minutes at room temperature. Then, the reaction solution was cooled to 0 ° C, and a solution of compound 8 (0.50 g, 1.34 bandol) in acetyl ether (4.0 ml) and topyldimethylsilyl triflate (0.77 mL, 3.35 nmol) were added. The mixture was stirred at the temperature for 7 hours. A saturated aqueous solution of sodium hydrogen carbonate was added to the reaction solution, extracted with a jet filter, the organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (elution solvent: n-hexane: ethyl acetate = 100: 1 → 5: 1) to obtain Compound 16 (oil, 0.36 g, yield 42.9%).
本品の1 H-NMRスぺク卜ルは実施例 7で得られた化合物 16のスぺクトルと一致した。 The 1 H-NMR spectrum of this product was identical to the spectrum of compound 16 obtained in Example 7.
実施例 10 Example 10
Figure imgf000022_0002
Figure imgf000022_0002
30 31 化合物 5 (0.30g,0.41mmol)をジクロロメタン(6.0mL)に溶解し、 -781でベンゼンスル ホン酸(0.07g,0.40mmol)を加え、 同温度で 2時間攪拌した。 さらにベンゼンスルホン酸 (0.14 0.80匪01)を加ぇ、 同温度で 6時間攪拌した。 反応液に飽和炭酸水素ナトリウム 水溶液を加え、ジクロロメタンで抽出し、 有機層を飽和食塩水で洗浄し、 無水硫酸マグ ネシゥムで乾燥後、 減圧濃縮した。 残渣 (HPLCより化合物 30 :化合物 31=24: 1)を 30 31 Compound 5 (0.30 g, 0.41 mmol) was dissolved in dichloromethane (6.0 mL), benzenesulfonic acid (0.07 g, 0.40 mmol) was added at -781, and the mixture was stirred at the same temperature for 2 hours. Further, benzenesulfonic acid (0.14 0.80 bandage 01) was added thereto, and the mixture was stirred at the same temperature for 6 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, and the mixture was extracted with dichloromethane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Residue (Compound 30: Compound 31 = 24: 1 by HPLC)
Figure imgf000023_0001
ο τ〜!: 牽 、 ¾
Figure imgf000023_0002
Figure imgf000023_0001
ο τ ~! : Towing, ¾
Figure imgf000023_0002
=ί 'ΡΡ) 62 ' (Ηΐ ·9 '9 '1=1 'ΡΡ) 80 '\ ' (Η8 ' L '8 ' (HZ 's) U 'S ' ( ¾) ·Ζ - 9 ·1 ' (HZ ' ZHO ·ί=ί '1) 89 'I ' (HZ 'πι) l-W ( Z\ 06 '1-62 T (HS '« OS '0 ' (H6 ' 06 ·0 ' (H6 's) 68 '0 ' (HS 's) Z ΐ ·0 ' (HS 's) Οΐ ·0 ' (HS ' 60 ·0 ' (H 's) 80 ·0 :uidd ρ (mOOZ ' ;) (D)丽- H ,  = ί 'ΡΡ) 62' (Ηΐ9 '9' 1 = 1 'ΡΡ) 80' \ '(Η8' L '8' (HZ 's) U' S '(¾) (HZ 'ZHO · ί = ί' 1) 89 'I' (HZ 'πι) lW (Z \ 06' 1-62 T (HS '«OS' 0 '(H6 '06 · 0' (H6 's) 68 '0' (HS 's) Z ΐ · 0' (HS 's) Οΐ · 0' (HS '60 · 0 '(H' s) 80 · 0: uidd ρ (mOOZ ';) (D) 丽-H,
(%L *88 '§SZ ,0) 0 £ 、Π
Figure imgf000023_0003
く、
(% L * 88 '§SZ, 0) 0 £, Π
Figure imgf000023_0003
And
U 【表 2】 U [Table 2]
3H), , , 4.38-4.43(m, IH), 3H),,, 4.38-4.43 (m, IH),
,
,
Figure imgf000024_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000025_0001
(i ^ ) 【z辇】  (i ^) [z 辇]
u u
iLLmi mz OAV 【表 2】 (続き 2 ) iLLmi mz OAV [Table 2] (continued 2)
Figure imgf000026_0001
Figure imgf000026_0001
2 ) 本発明により i3位の置換ェチェル側鎖は、 ァ位の保護された水酸基に対し高立体選 択的にトランス配置に導入され、 所望する高生理活性を有するトランス体を効率よく得 ることを可能にした (表 3参照) 。 表 3の右カラムに本発明での結果、 左カラムに従来 法の結果 (表 1 ) を示した。 2) According to the present invention, the substituted echel side chain at the i3 position is introduced into the trans configuration in a highly stereoselective manner with respect to the protected hydroxyl group at the a position to efficiently obtain a trans form having a desired high physiological activity. (See Table 3). The right column of Table 3 shows the results of the present invention, and the left column shows the results of the conventional method (Table 1).
寸 ID Dimension ID
CO  CO
 Dimension
00  00
Figure imgf000027_0001
Figure imgf000027_0001
3 ) 本発明の非水条件下での酸による脱トリアルキルシリル化反応は、 α側鎖を 3側鎖 に対し高立体選択的にトランス配置に制御することができる。 例として t-プチルジメ チルシリルエノ一ルエーテル体の脱トリアルキルシリルイ匕反応の結果を表 4に示した。 また、 比較のため含水系での結果を反応式 4に示した。 本発明の非水条件下での酸によ る脱トリアルキルシリル化反応でのトランス体:シス体の生成比は 24〜220: 1であり、 含水系での場合に比べ所望するトランス体が高立体選択的に得られた。 表 43) The detrialkylsilylation reaction with an acid under non-aqueous conditions of the present invention can control the α side chain to the trans configuration in a highly stereoselective manner with respect to the 3 side chains. As an example, Table 4 shows the results of the detrialkylsilyl terrifying reaction of the t-butyldimethylsilyl enol ether. For comparison, the results for the hydrous system are shown in Reaction Formula 4. The ratio of the trans-form to the cis-form in the detrialkylsilylation reaction by an acid under non-aqueous conditions of the present invention is from 24 to 220: 1, and the desired trans-form is higher than that in a water-containing system. Highly stereoselective. Table 4
Figure imgf000028_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000029_0001
4) 本発明に用いた化合物 1と化合物 8は、 以下に示す方法 (参考例 1〜13) で得る ことができるが、 本参考例に限定されるものではない。
Figure imgf000030_0001
4) Compound 1 and compound 8 used in the present invention can be obtained by the following methods (Reference Examples 1 to 13), but are not limited to these Reference Examples.
Figure imgf000030_0001
20 21  20 21
化合物 20 (100g,0.55mol)をメタノール(300mL)に溶解し、 チォグリコール酸メチル ( 64.5g,0.61mol)を加え室温で攪拌した。 これに 5°Cでナトリウムメトキシド (62.7g, 1.16mol)を 2時間かけて加え、 室温で 1時間攪拌した。 反応液に 0°Cで濃塩酸 (5. OmL)を 加え中和した後、 メタノールを約半量留去し、 更に水、 希塩酸を加え、 酢酸ェチルで抽 出した。 有機層を飽和食塩水で洗浄し、 無水硫酸マグネシウムで乾燥後、 減圧濃縮し、 粗化合物 21 (油状物, 120g,粗収率 105.8%)を得た。  Compound 20 (100 g, 0.55 mol) was dissolved in methanol (300 mL), and methyl thioglycolate (64.5 g, 0.61 mol) was added, followed by stirring at room temperature. To this was added sodium methoxide (62.7 g, 1.16 mol) at 5 ° C over 2 hours, and the mixture was stirred at room temperature for 1 hour. The reaction solution was neutralized by adding concentrated hydrochloric acid (5. OmL) at 0 ° C., about half of methanol was distilled off, water and diluted hydrochloric acid were added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain a crude compound 21 (oil, 120 g, crude yield 105.8%).
1 H-NMR(CDC13 , 200MHz) δ ppm;159-l.82 (m, 4H),2.39 (t, J-7. OHz, 2H) , 2.66 (t, J-7. OHz, 2H) ,3.23(s,2H),3.75(s,3H). 参考例 2
Figure imgf000030_0002
1 H-NMR (CDC1 3, 200MHz) δ ppm; 159-l.82 (m, 4H), 2.39 (. T, J-7 OHz, 2H), 2.66 (. T, J-7 OHz, 2H), 3.23 (s, 2H), 3.75 (s, 3H). Reference example 2
Figure imgf000030_0002
21 粗化合物 21 (115g, 0.56mol)を四塩化炭素(580mL)に溶解:し、 トリェチルァミン(59.7 g,0.59mol)を加え室温で攪拌した。 これに 0ででクロロアセチルクロライド (66.6g, 0.59mol)を 40分かけて加え、 3時間攪拌した。 析出した結晶を濾別し、 濾液にフラン( 59.6g, 0.88mol)、 三弗化ホウ素ジェチルェ一テル錯体(7. OOmL, 56mmol)を加え室温で、 16時間攪拌した。 反応液に 5%炭酸ナトリウム水溶液を加え、 クロ口ホルムで抽出し、 有機層を水洗し、 無水硫酸マグネシウムで乾燥後、 減圧濃縮し、 粗化合物 22 (油状物, 1 9g,粗収率 90.1%)を得た。  21 Crude compound 21 (115 g, 0.56 mol) was dissolved in carbon tetrachloride (580 mL), and triethylamine (59.7 g, 0.59 mol) was added, followed by stirring at room temperature. To this, chloroacetyl chloride (66.6 g, 0.59 mol) was added over 40 minutes at 0 and stirred for 3 hours. The precipitated crystals were separated by filtration, and to the filtrate were added furan (59.6 g, 0.88 mol) and boron trifluoride geethylether complex (7.OOmL, 56 mmol), and the mixture was stirred at room temperature for 16 hours. A 5% aqueous sodium carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give crude compound 22 (oil, 19 g, crude yield 90.1%). ).
'H-NMR(CDC13, 200MHz) δ ppm; 160-1.90 (m, 4H), 2.68 (t, J=7.0Hz, 2H) , 2.86(t, J=7.0Hz, 2H) , 3.23 (s, 2H), 3.7 (s, 3H), 6.54 (dd, J=l.6, 3.6Hz, 1H) , 7.19 (dd, J=0.8, 3.6Hz, 1H),7.59( dd, J=0.8, 1.6Hz,lH). 参考例 3 'H-NMR (CDC1 3, 200MHz) δ ppm; 160-1.90 (m, 4H), 2.68 (t, J = 7.0Hz, 2H), 2.86 (t, J = 7.0Hz, 2H), 3.23 (s, 2H), 3.7 (s, 3H), 6.54 (dd, J = l.6, 3.6Hz, 1H), 7.19 (dd, J = 0.8, 3.6Hz, 1H), 7.59 (dd, J = 0.8, 1.6Hz) , lH). Reference example 3
Figure imgf000031_0001
Figure imgf000031_0001
22 23 粗化合物 22 (129g,0.50mol)をメタノール(640mL)に溶解し、 2°Cで水素化ホウ素ナ トリゥム(7.23g, 0.19mol)を少量ずつ加え、 40分間攪拌した。 これに 2 %亜硫酸水素ナ トリウム水、 希塩酸を加え、 酢酸ェチルで抽出した。 有機層を飽和食塩水で洗浄し、 無 水硫酸マグネシウムで乾燥後、 減圧濃縮し、 粗化合物 23 (油状物, 97.5g,粗収率 75.2% )を得た。  22 23 Crude compound 22 (129 g, 0.50 mol) was dissolved in methanol (640 mL), sodium borohydride (7.23 g, 0.19 mol) was added little by little at 2 ° C., and the mixture was stirred for 40 minutes. To this was added 2% aqueous sodium hydrogen sulfite and diluted hydrochloric acid, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain a crude compound 23 (oil, 97.5 g, crude yield 75.2%).
1 H-NMR(CDC13 , 200MHz) δ ppm; 1.38-1.75 (m, 4H), 1.87 (q, J=7. OHz, 2H), 2.64 (t, J=7. OHz, 2H ),3.24(s, 2H) , 3.74 (s, 3H) , 4.69 (t, J=7. OHz, IH), 6.24 (dd, J-0.8, 3.6Hz, IH) , 6.34 (dd, J= 1.8,3.6Hz, IH) , 7.38 (dd, J=0.8, 1.8Hz, IH) . 参考例 4 1 H-NMR (CDC1 3, 200MHz) δ ppm; 1.38-1.75 (m, 4H), 1.87 (. Q, J = 7 OHz, 2H), 2.64 (. T, J = 7 OHz, 2H), 3.24 ( s, 2H), 3.74 (s, 3H), 4.69 (t, J = 7.OHz, IH), 6.24 (dd, J-0.8, 3.6Hz, IH), 6.34 (dd, J = 1.8,3.6Hz, IH), 7.38 (dd, J = 0.8, 1.8Hz, IH) .Reference Example 4
Figure imgf000031_0002
粗化合物 23 (92.5g, 0.36mol)を 1, 4 -ジォキサン(512mL)に溶解し、 塩化亜鉛水溶液( ZnCl2 : 185 1.3611101+ 0:30510を加ぇ加熱攪拌し、 還流を確認してから 2時間後、 1, 4-ジォキサンを留去した。 これに飽和炭酸水素ナトリゥム水溶液を加え酢酸ェチルで 抽出し、 有機層を飽和食塩水で洗浄し、 無水硫酸マグネシウムで乾燥後、 減圧濃縮し、 粗化合物 24 (油状物, 69.3g,粗収率 74.9%)を得た。
Figure imgf000031_0002
Crude compound 23 (92.5 g, 0.36 mol) was dissolved in 1,4-dioxane (512 mL), and an aqueous zinc chloride solution (ZnCl 2 : 185 1.3611101+ 0: 30510) was heated and stirred. After 1 hour, 1,4-dioxane was distilled off, a saturated aqueous sodium hydrogen carbonate solution was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Compound 24 (oil, 69.3 g, crude yield 74.9%) was obtained.
1 H -丽 R(CDC13, 200MHz) δ ppm;l.35-1.78 (m, 6H), 1.78-2.00 (m, 1H),2.20-2.30 (m, IH), 2.67 (t,2H),3.24 (s, 2H), 3.75 (s, 3H) ,4.71 (brs, IH) ,6.21 (dd, J=l.4, 5.8Hz, IH) ,7.51 (dd, J= 2.2, 5.8Hz, IH).
Figure imgf000032_0001
粗化合物 24 (69.1g,0.27mol)をトルエン(485mL)に溶解し、 トリェチルァミン(29. Og , 0.29mol),ク口ラール(2.08mL, 0.02mol)を加え室温で 2時間攪拌した。 反応液を直接シ リカゲルカラムクロマトグラフィー(溶出溶媒; n-へキサン:酢酸ェチル =3: 1→1: 2) に付し、 化合物 25 (油状物, 39.8g,化合物 20からの収率 30.9%)を得た。
1 H -丽R (CDC1 3, 200MHz) δ ppm; l.35-1.78 (m, 6H), 1.78-2.00 (m, 1H), 2.20-2.30 (m, IH), 2.67 (t, 2H), 3.24 (s, 2H), 3.75 (s, 3H), 4.71 (brs, IH), 6.21 (dd, J = l.4, 5.8Hz, IH), 7.51 (dd, J = 2.2, 5.8Hz, IH) .
Figure imgf000032_0001
Crude compound 24 (69.1 g, 0.27 mol) was dissolved in toluene (485 mL), and triethylamine (29. Og, 0.29 mol) and kualaral (2.08 mL, 0.02 mol) were added, followed by stirring at room temperature for 2 hours. The reaction solution was directly subjected to silica gel column chromatography (elution solvent; n-hexane: ethyl acetate = 3: 1 → 1: 2) to give Compound 25 (oil, 39.8 g, 30.9% yield from Compound 20). ).
1 H-NMR(CDC13 , 200MHz) (5 ppm; 1.58-1.69 (m, 4H) , 2.18-2.26 (m, 2H) , 2.32 (dd, J=2.0, 18.7Hz , 1H) , 2.64 (t, J=7.0Hz, 2H) , 2.83 (dd, J=6.2, 18.7Hz, 1H) ,3.22 (s, 2H) , 3.74 (s, 3H) , 4.94- 4,98(m, 1H),7.16-7.22 (m, 1H). 参考例 6 1 H-NMR (CDC1 3, 200MHz) (5 ppm; 1.58-1.69 (m, 4H), 2.18-2.26 (m, 2H), 2.32 (dd, J = 2.0, 18.7Hz, 1H), 2.64 (t, J = 7.0Hz, 2H), 2.83 (dd, J = 6.2, 18.7Hz, 1H), 3.22 (s, 2H), 3.74 (s, 3H), 4.94-4,98 (m, 1H), 7.16-7.22 (m, 1H). Reference Example 6
Figure imgf000032_0002
Figure imgf000032_0002
化合物 25 (20. Og, 77.4mmol)をジクロロメタン(200iuL)に溶解し、 - 10°Cで卜リエチル アミン(4.9.0g,0.4.8mol)、 t-プチルジメチルシリルクロライド(23.3g, 0.16mol)、 4 -ジメ チルァミノピリジン(5.90g, 48.3腿 ol)を加え 2.5時間攪拌後、 水を加え、 ジクロロメタ ンで抽出した。 有機層を無水硫酸マグネシウムで乾燥後、 減圧濃縮し、 残渣をシリカゲ ルカラムクロマトグラフィー (溶出溶媒; n-へキサン:酢酸ェチル =10: 1→5: 1)に付 し、 化合物 8 (26.5g,収率 88.5%)を得た。  Compound 25 (20. Og, 77.4 mmol) was dissolved in dichloromethane (200 iuL), and triethylamine (4.9.0 g, 0.4.8 mol), t-butyldimethylsilyl chloride (23.3 g, 0.16 mol) was dissolved at -10 ° C. , 4-Dimethylaminopyridine (5.90 g, 48.3 tmol) was added, and after stirring for 2.5 hours, water was added and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography (elution solvent; n-hexane: ethyl acetate = 10: 1 → 5: 1) to give compound 8 (26.5 g). , Yield 88.5%).
'H-NMR(CDC13 ,200MHz) (5 pm;0.12(s,3H),0.13 (s, 3H) , 0.91 (s, 9H) , 1.53-1.70 (ra, 4H) , 2.15-2.23 (m, 2H), 2.27 (dd, J=2.2, 18.7Hz, 1H),2.65 (t, J=6.8Hz, 2H) , 2.7 (dd, J=6.0, 18.7 Hz, 1H) ,3.22(s, 2H), 3.7 (s, 3H), 4.85-4.93 (m, 1H) , 7.04-7.08 On, 1H) . 参考例 7 'H-NMR (CDC1 3, 200MHz) (5 pm; 0.12 (s, 3H), 0.13 (s, 3H), 0.91 (s, 9H), 1.53-1.70 (ra, 4H), 2.15-2.23 (m, 2H), 2.27 (dd, J = 2.2, 18.7Hz, 1H), 2.65 (t, J = 6.8Hz, 2H), 2.7 (dd, J = 6.0, 18.7 Hz, 1H), 3.22 (s, 2H), 3.7 (s, 3H), 4.85-4.93 (m, 1H), 7.04-7.08 On, 1H). Reference Example 7
Figure imgf000033_0001
酢酸ビニル(5(kL)にアルゴン雰囲気下、 リパーゼ(10. 2g)を懸濁させ、 さらに酢酸ビ ニル (30mL)に溶解した化合物 2 5 (9. 57g、 37. 0腿 oL)を加え室温で 2日間攪拌した。 次い で、 反応液をセライトを用いて濾過し、 濾液を減圧濃縮し化合物 2 6 aと 2 7の混合物( 油状物, 11. 5g)を得た。 参考例 8
Figure imgf000033_0001
Lipase (10.2 g) was suspended in vinyl acetate (5 (kL) under an argon atmosphere, and compound 25 (9.57 g, 37.0 tL) dissolved in vinyl acetate (30 mL) was added. Then, the reaction solution was filtered using celite, and the filtrate was concentrated under reduced pressure to obtain a mixture of compounds 26a and 27 (oil, 11.5 g).
Figure imgf000033_0002
粗化合物 2 6 aと 2 7の混合物(11. 5g)をジクロロメタン(106mL)に溶解し、 - 1 (T で.. トリェチルァミン (3. 76g, 37. 2mmol)、 メ夕ンスルホニルク口ライド (4, 27g, 37. 3腿 o l)を 加え 1時間攬拌した。 次いで、 反応液を飽和炭酸水素ナトリゥム水溶液および水で洗浄 し、 無水硫酸マグネシゥムで乾燥後、 減圧濃縮し、 粗化合物 2 6 aと 2 8の混合物 (油状 物, 12. 4g)を得た。 参考例 9
Figure imgf000033_0002
A mixture of the crude compounds 26a and 27 (11.5 g) was dissolved in dichloromethane (106 mL), and -1 (at T ..) triethylamine (3.76 g, 37.2 mmol), and methyl sulfonyl chloride (4, The reaction mixture was washed with saturated aqueous sodium hydrogen carbonate solution and water, dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and concentrated to give crude compounds 26a and 2g. A mixture of 8 (oil, 12.4 g) was obtained.
Figure imgf000033_0003
粗化合物 2 6 aと 2 8の混合物(12. 4g)に酢酸セシウム(10. 8g, 56. 3腿 o l)の t -ブチル アルコール(90mL)溶液を加え室温で 14時間攪拌した。 次いで、 反応液に水を加え、 酢酸 ェチルで抽出し、 有機層を無水硫酸 乾燥後、 減圧濃縮し、 粗化合物
Figure imgf000033_0003
To a mixture (12.4 g) of the crude compounds 26a and 28 was added a solution of cesium acetate (10.8 g, 56.3 mol) in t-butyl alcohol (90 mL), and the mixture was stirred at room temperature for 14 hours. Next, water is added to the reaction solution, and acetic acid is added. The organic layer was dried over sulfuric anhydride and concentrated under reduced pressure to give the crude compound.
26 b (油状物, 11.2g)を得た。 参考例 10 26 b (oil, 11.2 g) was obtained. Reference example 10
Figure imgf000034_0001
Figure imgf000034_0001
粗ィ匕合物 2 6 b (11.2g)をメタノール(1 OOniL)に溶解し、 0°Cで、 0.5Mグァ二:  Dissolve 26b (11.2 g) in methanol (1 OOniL), and at 0 ° C, 0.5 M
—ル溶液 (82mL, 41匪 ol)を加え 1時間攪拌した。 次いで、 酢酸(2.50g, 41.6匪 ol)を加え 、 反応液を減圧濃縮した。 残渣を酢酸ェチルに溶解後、 水洗し、 有機層を無水硫酸マグ ネシゥムで乾燥後、 減圧濃縮し、 粗化合物 2 9 a (油状物, 9.70g)を得た。 参考例 11 To the mixture was added a toluene solution (82 mL, 41 bandol), and the mixture was stirred for 1 hour. Then, acetic acid (2.50 g, 41.6 ol) was added, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water, and the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to obtain a crude compound 29a (oil, 9.70 g). Reference Example 11
Figure imgf000034_0002
酢酸ビニル(lOOmL)にアルゴン雰囲気下、 リパーゼ (20.3g)を加え懸濁させ、 これに酢 酸ビニル (60mL)に溶解した粗化合物 29a(9.70g)を加え 2日間攪拌した。 次いで、 反応 液をセライトを用いて濾過し、 濾液を減圧濃縮後、 残渣をシ
Figure imgf000034_0002
Lipase (20.3 g) was added and suspended in vinyl acetate (100 mL) under an argon atmosphere, and crude compound 29a (9.70 g) dissolved in vinyl acetate (60 mL) was added thereto, followed by stirring for 2 days. Then, the reaction solution was filtered using Celite, and the filtrate was concentrated under reduced pressure.
ラフィ一に付し、 粗化合物 26c (油状物, 8.69g)を得た。 The crude compound 26c (oil, 8.69 g) was obtained.
参考例 12
Figure imgf000035_0001
Reference Example 12
Figure imgf000035_0001
粗化合物 26c(8.67g)をメタノール (90mL)に溶解し、 0°Cで、 0.5Mグァ二:  The crude compound 26c (8.67 g) was dissolved in methanol (90 mL) and, at 0 ° C, 0.5 M guar:
ール溶液(63mL, 31.5腿 ol)を加え 1時間攪拌した。 次いで、 酢酸(1.92g, 31.9匪 ol)を加 え、 反応液を減圧濃縮した。 残渣を酢酸ェチルに溶解後、 水洗し、 有機層を無水硫酸マ グネシゥムで乾燥後、 減圧濃縮し、 残渣をシリカゲルカラムクロマトグラフィー (溶出 溶媒; n-へキサン:酢酸ェチル =3: 1→1: )に付し、 化合物 29 b (油状物, 5.57g,化合 物 25からの収率 58.2%,光学純度 99.8%ee)を得た。 Solution (63 mL, 31.5 tmol) was added and stirred for 1 hour. Then, acetic acid (1.92 g, 31.9 marl) was added, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with water, the organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography (elution solvent: n-hexane: ethyl acetate = 3: 1 → 1: ) To give compound 29b (oil, 5.57 g, 58.2% yield from compound 25, optical purity 99.8% ee).
1 H-NMR(CDC13, 200MHz) <5 ppm; 1.58—1.69 (m, 4H), 2.18-2.26 (m, 2H) , 2.32 (dd, J=2.0,18.7 Hz, 1H),2.64(t, J=7. OHz, 2H): 2.83 (dd, J=6.2, 18.7Hz, IH) , 3.22 (s, 211) , 3.7 (s, 3H) , 4.94- 4.98(m, lH),7.16-7.22(m, IH). 参考例 1 3 1 H-NMR (CDC1 3, 200MHz) <5 ppm; 1.58-1.69 (m, 4H), 2.18-2.26 (m, 2H), 2.32 (dd, J = 2.0,18.7 Hz, 1H), 2.64 (t, J = 7. OHz, 2H): 2.83 (dd, J = 6.2, 18.7Hz, IH), 3.22 (s, 211), 3.7 (s, 3H), 4.94-4.98 (m, lH), 7.16-7.22 ( m, IH). Reference Example 1 3
Figure imgf000035_0002
化合物 29 b (2. 9g, 9.63mmol)をジクロロメタン(25ml)に溶 ί挥し、 _15°Cでトリェチル ァミン(6.7niL,48.1匪 ol)、 t-ブチルジメチルシリルクロライド (2.92g, 19.3腿 ol)、 4-ジ メチルアミノビリジン(0.59g,4.81匪 ol)を加え 0°Cで 3時間攪拌した。 次いで、 水を加 え、 ジクロロメタンで抽出し、 有機層を無水硫酸マグネシウムで乾燥後、 減圧濃縮し、 残渣をシリカゲルカラムクロマトグラフィー(溶出溶媒; n-へキサン:酢酸ェチル =10 : 1→5: 1)に付し、 化合物 1 (3.33g, 92.7%)を得た。
Figure imgf000035_0002
Compound 29b (2.9 g, 9.63 mmol) was dissolved in dichloromethane (25 ml), and triethylamine (6.7 niL, 48.1 marl) and t-butyldimethylsilyl chloride (2.92 g, 19.3 mol) were dissolved at -15 ° C. ), And 4-dimethylaminoviridine (0.59 g, 4.81 marl) were added and the mixture was stirred at 0 ° C for 3 hours. Then, water is added, extracted with dichloromethane, the organic layer is dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and the residue is subjected to silica gel column chromatography (elution solvent: n-hexane: ethyl acetate = 10: 1 → 5: By subjecting to 1), compound 1 (3.33 g, 92.7%) was obtained.
1 H-匪 R(CDC13, 200MHz) <5 ppm; 0.1 (s, 3H) , 0.13 (s, 3H) , 0.91 (s, 9H) , 1.56-1.68 (m, 4H) , 2.15-2.22 (m, 2H) , 2.27 (dd, J=2.2, 18.7Hz, IH) , 2.65 (t, J=6.8Hz, 2H) , 2.74 (dd, J=6.0, 18.7 Hz, 1H), 3. 22 (s, 2H) , 3. 74 (s, 3H), 4. 85-4. 92 (m, 1H), 7. 02-7. 10 (m, 1H) . 産業上の利用可能性 1 H- negation R (CDC1 3, 200MHz) < 5 ppm; 0.1 (s, 3H), 0.13 (s, 3H), 0.91 (s, 9H), 1.56-1.68 (m, 4H), 2.15-2.22 (m , 2H), 2.27 (dd, J = 2.2, 18.7Hz, IH), 2.65 (t, J = 6.8Hz, 2H), 2.74 (dd, J = 6.0, 18.7 Hz, 1H), 3.22 (s, 2H), 3.74 (s, 3H), 4.85-4.92 (m, 1H), 7.02-7.10 (m, 1H). Availability on
本発明の製造方法は、 従来法よりも安全に、 所望のひ側鎖を有する α ,ァ-置換シクロべ ン夕ノン誘導体の β位に種々の置換ェチェル基を良好な収率かつ高立体選択的に導入す ることを可能とし、 工業適性のある医薬またはその中間体として極めて有用な Q!,;3 , ァ-置換シクロペン夕ノン誘導体合成を提供することができる。 The production method of the present invention provides a safer and more stereoselective method for various substituted ethyl groups at the β-position of an α, α-substituted cyclobennone derivative having a desired side chain than the conventional method. It is possible to provide a synthesis of Q !, a 3, α-substituted cyclopentenonone derivative, which is very useful as an industrially suitable drug or an intermediate thereof.

Claims

請求の範囲 The scope of the claims
下記式 [I]  The following formula [I]
Figure imgf000037_0001
中、 Aは式 [I I]
Figure imgf000037_0001
Where A is the formula [II]
-t(CH2) X'5 rE(CH2 X2J - CH2 7- [I I ] -t (CH 2 ) X'5 r E (CH 2 X 2 J- CH 2 7- [II]
(式中、 X1及び X2は同一または異なって酸素原子、 硫黄原子、 メチレン基、 ビニレン基 、 ェチニレン基またはァレニレン基を示し、 n及び qは同一または異なって 0〜 6の整数 を示し、 m及び pは同一または異なって 0〜 2の整数を示し、 rは 0〜3の整数を示す。 ) で表される基を示し、 R1は水素原子、 二トリル基、 -OR6 (式中、 R5は水酸基の保護基 を示す。 ) または- C00R7 (式中、 R7は置換もしくは無置換の炭素原子数 1〜1 0個のァ ルキル基、 置換もしくは無置換の炭素原子数 2〜1 0個のアルケニル基、 置換もしくは 無置換の炭素原子数 2〜1 0個のアルキニル基、 置換もしくは無置換の炭素原子数 3〜 1 0個のシクロアルキル基、 置換もしくは無置換のフエニル基またはカルボキシル基の 保護基を示す。 ) を示し、 R2は水酸基の保護基を示す。 ] で表されるひ,ァ-置換シクロ (In the formula, X 1 and X 2 are the same or different and represent an oxygen atom, a sulfur atom, a methylene group, a vinylene group, an ethynylene group or an arelenylene group, and n and q are the same or different and represent an integer of 0 to 6, m and p are the same or different and each represents an integer of 0 to 2, r represents an integer of 0 to 3.), R 1 represents a hydrogen atom, a nitrile group, -OR 6 (formula Wherein, R 5 represents a hydroxyl-protecting group.) Or -C00R 7 (wherein, R 7 is a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, a substituted or unsubstituted carbon atom number) 2 to 10 alkenyl groups, substituted or unsubstituted alkynyl groups of 2 to 10 substituted or unsubstituted cycloalkyl groups of 3 to 10 carbon atoms, substituted or unsubstituted phenyl a group or a protecting group of carboxyl group.) indicates, R 2 is a protecting group for a hydroxyl group It is. ], Substituted α-substituted cyclo
'誘導体と、 下記式 [I I I]
Figure imgf000037_0002
'The derivative and the following formula [III]
Figure imgf000037_0002
[式中、 Mは BrZnまたは LiR8 3Al (式中、 R8は炭素原子数 1〜 6個のアルキル基を示す。 ) を示し、 R3は置換もしくは無置換の炭素原子数 1〜1 0個のアルキル基、 置換もしく は無置換の炭素原子数 2〜1 O f固のアルケニル基、 置換もしくは無置換の炭素原子数 2 〜1 0個のアルキニル基、 置換もしくは無置換の炭素原子数 3〜1 0個のシクロアルキ ル基、 置換もしくは無置換の炭素原子数 3〜1 0個のシクロアルキルォキシ基、 置換も しくは無置換のフエニル基または置換もしくは無置換のフエノキシ基を示し、 Zは水素 原子または Z'R4 (式中、 Z'は酸素原子または硫黄原子を示し、 は水酸基の保護基また はチオール基の保護基を示す。 ) を示す。 ]で表される有機金属試薬とをトリアルキル シリル卜リフラ一卜の存在下、 反応させることを特徴とする下記式 [IV] [In the formula, M (wherein, R 8 is. Represents an alkyl group of one to six carbon atoms) BrZn or LiR 8 3 Al indicates, R 3 is a substituted or unsubstituted carbon atoms 1 to 1 0 alkyl groups, substituted or unsubstituted carbon atoms 2 to 1 Off solid alkenyl groups, substituted or unsubstituted carbon atoms 2 1 to 10 alkynyl groups, substituted or unsubstituted cycloalkyl groups having 3 to 10 carbon atoms, substituted or unsubstituted cycloalkyloxy groups having 3 to 10 carbon atoms, substituted or unsubstituted Represents an unsubstituted phenyl group or a substituted or unsubstituted phenoxy group; Z represents a hydrogen atom or Z'R 4 (wherein Z 'represents an oxygen atom or a sulfur atom; represents a hydroxyl-protecting group or a thiol group. Represents a protecting group. Characterized by reacting with an organometallic reagent represented by the following formula [IV]:
Figure imgf000038_0001
Figure imgf000038_0001
[式中、 R まトリアルキルシリル基を示し、 A、 R1 , R2、 Rおよび Zは前記と同意義である ]で表される α, /3,ァ-置換シクロペン夕ノン卜リアルキルシリルエノ一ルエーテル体 の製造法。 Wherein R represents a trialkylsilyl group, and A, R 1 , R 2 , R and Z are as defined above. A method for producing a silyl enol ether compound.
2 . 請求項 1記載の式 [IV] [式中、 R5はトリアルキルシリル基を示し、 A、 R R2、 R3お よび Zは前記と同意義である。 ]で表わされる α , β ,了-置換シクロペン夕ノントリアル キルシリルエノ一ルェ一テル体に非水条件下、 酸を作用させて脱卜リアルキルシリル化 することを特徴とする下記式 [V] 2. The formula [IV] according to claim 1, wherein R 5 represents a trialkylsilyl group, and A, RR 2 , R 3 and Z are as defined above. [V] wherein the α, β, β-substituted cyclopentene non-trialkylsilyl enol ester represented by the formula [V]
Figure imgf000038_0002
Figure imgf000038_0002
[式中 A、 R R2、 R3および Zは前記と同意義である。 ]で表わされる α, β ,ァ-置換シク '誘導体の製造法。 Wherein A, RR 2 , R 3 and Z are as defined above. Α, β, α-substituted 'Methods for producing derivatives.
3 . 請求項 1記載の式 [I] [式中、 A、 R1及び R2は前記と同意義である。 ]で表されるひ, ァ-置換シクロペンテノン誘導体と式 [II I] [式中、 R3、 M及び Zは前記と同意義である。 ] で表される有機金属試薬とを反応させる際に、 トリアルキルシリルトリフラートを 1当 量以上用いることを特徴とする下記式 [V] 3. The formula [I] according to claim 1, wherein A, R 1 and R 2 are as defined above. And the formula [II I] wherein R 3 , M and Z are as defined above. Wherein at least one equivalent of a trialkylsilyl triflate is used in the reaction with the organometallic reagent represented by the formula [V]
Figure imgf000039_0001
Figure imgf000039_0001
[式中 A、 R R2、 R3および Zは前記と同意義である。 ]で表される c¾ , /3 ,ァ-置換シクロ Wherein A, RR 2 , R 3 and Z are as defined above. C¾, / 3, α-substituted cyclo
'誘導体の製造法。  'Methods for producing derivatives.
PCT/JP2004/004484 2003-03-31 2004-03-30 PROCESS FOR PRODUCING α,ß,Ϝ-SUBSTITUTED CYCLOPENTANONE DERIVATIVE WO2004087724A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005504234A JP4591778B2 (en) 2003-03-31 2004-03-30 Process for producing α, β, γ-substituted cyclopentanone derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-093247 2003-03-31
JP2003093247 2003-03-31

Publications (1)

Publication Number Publication Date
WO2004087724A1 true WO2004087724A1 (en) 2004-10-14

Family

ID=33127354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/004484 WO2004087724A1 (en) 2003-03-31 2004-03-30 PROCESS FOR PRODUCING α,ß,Ϝ-SUBSTITUTED CYCLOPENTANONE DERIVATIVE

Country Status (2)

Country Link
JP (1) JP4591778B2 (en)
WO (1) WO2004087724A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04270294A (en) * 1991-02-26 1992-09-25 Fumie Satou Alpha-methylenecyclopentanone derivative and its production
JPH05294924A (en) * 1992-04-21 1993-11-09 Taisho Pharmaceut Co Ltd Prostaglandin e1 analog

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4029251B2 (en) * 1997-02-04 2008-01-09 小野薬品工業株式会社 ω-cycloalkyl-prostaglandin E2 derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04270294A (en) * 1991-02-26 1992-09-25 Fumie Satou Alpha-methylenecyclopentanone derivative and its production
JPH05294924A (en) * 1992-04-21 1993-11-09 Taisho Pharmaceut Co Ltd Prostaglandin e1 analog

Also Published As

Publication number Publication date
JP4591778B2 (en) 2010-12-01
JPWO2004087724A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
US6700025B2 (en) Process for stereoselective synthesis of prostacyclin derivatives
Asaoka et al. The reactions of 2-(trimethylsiloxy) furans with orthocarboxylic esters, acetals, and acylal in the presence of Lewis acids.
Akiyama et al. Stereoselective synthesis of cyclopentanols by Lewis acid-mediated [3+ 2] annulation of allyldiisopropylphenylsilane with α, β-unsaturated diesters
KR20190009326A (en) Process for preparing eribulin and its intermediates
Yamada et al. Reaction of perfluorocyclopentene with various carbon nucleophiles—heteroaromatic lithium reagents, enolate and phosphonium ylide
WO2004087724A1 (en) PROCESS FOR PRODUCING α,ß,Ϝ-SUBSTITUTED CYCLOPENTANONE DERIVATIVE
WO2022107463A1 (en) Method for producing ketone derivative
Stanway et al. 1, 5-Stereocontrol in tin (IV) halide mediated reactions between N-and S-substituted pent-2-enylstannanes and aldehydes or imines
WO2014094511A1 (en) Intermediates for synthesizing treprostinil and preparation method thereof as well as the preparation method of treprostinil thereby
CN111263750B (en) Process for producing prostaglandin derivative
JP2015013851A (en) PRODUCTION METHOD OF (2R)-2-FLUORO-2-C-METHYL-D-RIBONO-γ-LACTONE
JP4234939B2 (en) Cyclic acetylene compound and process for producing the same
CN112724060B (en) Novel process for producing prostaglandin and intermediate
JP6230528B2 (en) Process for producing optically active 2-vinylcyclopropane-1,1-dicarboxylic acid ester
JP4811547B2 (en) Process for producing optically active cyclohexene compound and optically active cyclohexene derivative used for the production
JP3618815B2 (en) Method for producing chloroalkylsulfonyl chloride
JP3758707B2 (en) (-)-Trans-coumaucine production method and novel intermediate
WO2016199789A1 (en) Method of manufacturing trifluoromethyl substituted semisquarate, method of manufacturing trifluoromethyl compound starting from trifluoromethyl substituted semisquarate, and trifluoromethyl group-containing compound
JP4162891B2 (en) Method for producing tetrahydrothiophene derivative
KR101176892B1 (en) Method of preparing methylgerambullone and intermediates therefor
JP3823668B2 (en) Sphingomyelin analogs and methods for their production
Frye et al. Asymmetric Chemical Synthesis of (R)-and (S)-Citramalate in High Enantiomeric Purity
JPH10101614A (en) Production of alpha alpha-difluoro-beta-hydroxy ester
JPH07233175A (en) Asymmetric production of metal-substituted cyclopropylmethanol derivative.
JP4060718B2 (en) New production method of enol ether

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005504234

Country of ref document: JP

122 Ep: pct application non-entry in european phase
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)